{
  "specialty": "rheumatology",
  "abstracts": [
    "1. pediatr rheumatol online j. 2025 jul 1523172. doi 10.1186s1296902501127x. immune checkpoint inhibitors and the pediatric rheumatologist a pediatric needs assessment. storwick j1 ye c2 jamal s3 maltez n4 chan m5. author information 1division of pediatric rheumatology british columbia childrens hospital the university of british columbia vancouver bc canada. john.storwickalbertahealthservices.ca. 2department of medicine university of alberta edmonton ab canada. 3department of medicine university of british columbia arthritis research canada vancouver bc canada. 4department of medicine university of ottawa ottawa on canada. 5division of pediatric rheumatology british columbia childrens hospital the university of british columbia vancouver bc canada. background the use of immune checkpoint inhibitor ici therapy is increasing in pediatric oncology. icis can cause rheumaticimmune related adverse events rhiraes such as inflammatory arthritis and myositis. few case reports detail rhiraes and their management in the pediatric population. our objective was to assess the familiarity of pediatric rheumatologists prs worldwide with rhiraes gauge confidence in managing these conditions and identify knowledge gaps to guide future educational efforts. methods we circulated an online survey to 2084 prs via the dr. peter dent pediatric rheumatology bulletin board. responses were collected from june 2024 to september 2024. we collected data on practitioner demographics knowledge of icis and rhiraes confidence in managing rhiraes and preferred educational resources. results sixtynine participants responded of which 55 80 were prs from academic centers. despite global distribution 56 81 responses came from north america. thirtyfour 49 respondents were not aware of icis and their related mechanisms indications and side effects and 40 58 were not familiar with iraes. fiftyfive 80 had never managed a patient with rhiraes. among those who had 1469 21 the median number of cases managed was 2.0 iqr 0.0. thirtynine respondents were not confident at all managing rhiraes 34 were not confident at all managing preexisting autoimmune diseases pad in ici users and 46 were not confident at all advising oncology colleagues on initiating or discontinuing icis in the context of rhiraes or preexisting autoimmune diseases pad. no respondents felt completely confident managing these conditions. participants identified knowledge gaps in longterm management acute management and recognition and diagnosis. fortythree indicated the need for pediatricspecific clinical guidelines. of the 14 respondents with clinical experience treating rhiraes treatment varied with 4 using nonsteroidal antiinflammatory drugs 3 using prednisone and 4 combining prednisone with methotrexate. longterm management also varied with 5 using methotrexate and 3 using tumor necrosis factor inhibitors. conclusions significant knowledge gaps and a lack of confidence exist among prs managing icirelated rhiraes. as ici use increases in pediatric oncology prs exposure to rhiraes will follow. targeted educational programs and clinical guidelines may be valuable to address these gaps. 2025. the authors. doi 10.1186s1296902501127x pmcid pmc12261645 pmid 40665314 indexed for medline conflict of interest statement declarations. competing interests the authors declare no competing interests. ethics approval and consent to participate obtained through ethics review board of the university of british columbia ethics approval h2303354. consent for publication not applicable. competing interests the authors declare that they have no competing interests.",
    "2. rheumatol int. 2025 jul 4457165. doi 10.1007s00296025059223. digital empowerment on hold diga adoption gapsa german national crosssectional patient survey study. kremer p1 fink d2 morf h3 labinsky h4 gente k5 aries p6 krusche m1 muehlensiepen f7 kuhn s8 hueber a9 knitza j10. author information 1division of rheumatology and systemic inflammtory diseases iii. department of medicine university medical center hamburgeppendorf hamburg germany. 2rheumazentrum mittelhessen bad endbach germany. 3department of medicine 3 rheumatology immunology friedrich alexanderuniversitt fau erlangennrnberg and uniklinikum erlangen erlangen germany. 4department of internal medicine 2 rheumatologyclinical immunology university hospital wrzburg wrzburg germany. 5internal medicine v hematology oncology and rheumatology heidelberg university hospital heidelberg germany. 6department of rheumatology immunologikum hamburg germany. 7center for health services research faculty of health sciences brandenburg medical school theodor fontane rdersdorf germany. 8school of medicine institute for digital medicine philippsuniversitt marburg marburg germany. 9department internal medicine 5 division of rheumatology klinikum nuremberg paracelsus medical university nuremberg germany. 10school of medicine institute for digital medicine philippsuniversitt marburg marburg germany. knitzaunimarburg.de. digital health applications digas prescribable and reimbursed in germany since 2020 have the potential to enhance patient selfmanagement. this study aimed to assess rheumatology patients awareness willingness to use suitability and actual adoption of digas. between february 17 and april 8 2025 adult patients attending seven german rheumatology outpatient clinics completed an electronic survey. a total of 246 patients participated mean age 50.4 years 71.1 female with most treated at university hospitals 59.8. the predominant diagnoses were rheumatoid arthritis 41.1 psoriatic arthritis 18.3 and axial spondyloarthritis 10.2. while only 19.5 reported prior use of medical apps 39.8 were aware of digas and 12.6 had used one. notably 84.6 reported at least one comorbidity matching an approved diga indication most commonly back pain 54.8 chronic pain 52.0 and sleep disorders 35.8. a majority expressed willingness to regularly use a diga 72.4 and were open to recommendations from their rheumatologists or health insurers 72.8. additionally 76.0 showed interest in a rheumatologyspecific diga. despite high interest and relevant comorbidities among patients current diga use was limited. these findings underscore the need for targeted implementation strategies to increase uptake and realize the full potential of digital health applications in rheumatology care. the results also emphasize the need for rheumatologists to actively educate and guide their patients regarding the availability and potential benefits of digas. 2025. the authors. doi 10.1007s00296025059223 pmcid pmc12227445 pmid 40613892 indexed for medline conflict of interest statement declarations. ethical approval the philippsuniversity marburg research ethics committee confirmed on february 11 2025 that no ethical approval was required 2545 anz as the survey was anonymous.",
    "3. sci rep. 2025 jul 115120944. doi 10.1038s41598025052945. deep learning for occupation recognition and knowledge discovery in rheumatology clinical notes. madridgarca a1 prezsancristobal i2 leon l2 absolo l2 fernndezgutirrez b2 rodrguezrodrguez l3. author information 1grupo de patologa musculoesqueltica hospital clnico san carlos instituto de investigacin sanitaria san carlos idissc prof. martin lagos sn 28040 madrid spain. fredymadmsn.com. 2grupo de patologa musculoesqueltica hospital clnico san carlos instituto de investigacin sanitaria san carlos idissc prof. martin lagos sn 28040 madrid spain. 3grupo de patologa musculoesqueltica hospital clnico san carlos instituto de investigacin sanitaria san carlos idissc prof. martin lagos sn 28040 madrid spain. lrrodriguezsalud.madrid.org. occupational data is a crucial social determinant of health influencing diagnostic accuracy treatment strategies and policymaking in healthcare. however its inclusion in electronic health records ehr is often relegated to unstructured fields. this study aims to assess the collection and use of occupationrelated data in rheumatology clinical narratives describe factors influencing its collection and analyze its association with patient diagnoses. we employed a pretrained spanish language model finetuned with biomedical texts to identify occupation mentions in the ehr of 35586 rheumatic patients. the models performance was evaluated using a goldstandard dataset with precision recall and f1score metrics. occupation mentions were normalized using the european skills competences qualifications and occupations esco classification. logistic regression analyses identified sociodemographic and clinical predictors of occupation collection and examined associations between occupations and diagnoses. the model achieved an f1score of 0.73 identifying valid occupation mentions in 3527 patients 10. normalization yielded 402 esco codes. mechanical pathologies such as back pain and muscle disorders were associated with a higher probability of occupation collection while professions like cleaners and helpers were linked to these conditions. customer service clerks and hairdressers were associated with autoimmune diseases. this study demonstrates the feasibility of automated occupation recognition in ehrs highlighting the relevance of occupational data as a social determinant of health in rheumatology. integrating such data could inform targeted prevention and treatment strategies for rheumatic diseases. 2025. the authors. doi 10.1038s41598025052945 pmcid pmc12219523 pmid 40596267 indexed for medline conflict of interest statement declarations. competing interests the authors declare no competing interests. ethical approval comit de tica de la investigacin con medicamentos hospital clnico san carlos ethics review board approval 23340e was obtained as a retrospective study and waiver of informed consent was obtained for the use of unidentified clinical records. furthermore the study was conducted in accordance with the declaration of helsinki. miclaim checklist was used to report the results of this study see supplementary material miclaim checklist.",
    "4. curr rheumatol rep. 2025 jun 2827128. doi 10.1007s1192602501193w. emerging artificial intelligence innovations in rheumatoid arthritis and challenges to clinical adoption. gilvaz vj1 sudheer a2 reginato am34. author information 1division of rheumatology department of internal medicine rhode island hospital warren alpert medical school of brown university providence ri usa. vjosephgilvazbrownhealth.org. 2department of internal medicine saint vincent hospital worcester ma usa. 3division of rheumatology department of internal medicine rhode island hospital warren alpert medical school of brown university providence ri usa. 4department of dermatology rhode island hospital warren alpert medical school of brown university providence ri usa. purpose of review this review was written to inform practicing clinical rheumatologists about recent advances in artificial intelligence ai based research in rheumatoid arthritis ra using accessible and practical language. we highlight developments from 2023 to early 2025 across diagnostic imaging treatment prediction drug discovery and patientfacing tools. given the increasing clinical interest in ai and its potential to augment care delivery this article aims to bridge the gap between technical innovation and realworld rheumatology practice. recent findings several ai models have demonstrated high accuracy in early ra detection using imaging modalities such as thermal imaging and nuclear scans. predictive models for treatment response have leveraged routinely collected electronic health record ehr data moving closer to practical application in clinical workflows. patientfacing tools like mobile symptom checkers and large language models llms such as chatgpt show promise in enhancing education and engagement although accuracy and safety remain variable. ai has also shown utility in identifying novel biomarkers and accelerating drug discovery. despite these advances as of early 2025 no aibased tools have received fda approval for use in rheumatology in contrast to other specialties. artificial intelligence holds tremendous promise to enhance clinical care in rafrom early diagnosis to personalized therapy. however clinical adoption remains limited due to regulatory technical and implementation challenges. a streamlined regulatory framework and closer collaboration between clinicians researchers and industry partners are urgently needed. with thoughtful integration ai can serve as a valuable adjunct in addressing clinical complexity and workforce shortages in rheumatology. 2025. the authors under exclusive licence to springer sciencebusiness media llc part of springer nature. doi 10.1007s1192602501193w pmid 40580343 indexed for medline conflict of interest statement declarations. competing interests the authors declare no competing interests.",
    "5. int j rheum dis. 2025 jun286e70310. doi 10.11111756185x.70310. evidence and consensusbased recommendations for the screening diagnosis and management of secondary hypogammaglobulinemia in patients with systemic autoimmune rheumatic diseases by the taiwan college of rheumatology experts. tsao yp123 chen hh456 hsieh ty7 li kj89 yu kh1011 cheng tt1112 tseng jc1314 lu cc1516 chen dy171819. author information 1division of allergy immunology and rheumatology department of medicine taipei veterans general hospital taipei taiwan. 2division of holistic and multidisciplinary medicine department of medicine taipei veterans general hospital taipei taiwan. 3school of medicine national yang ming chiao tung university taipei taiwan. 4department of postbaccalaureate medicine college of medicine national chung hsing university taichung taiwan. 5department of industrial engineering and enterprise information tunghai university taichung taiwan. 6division of translational medicine taichung veterans general hospital taichung taiwan. 7clinical skill training center department of medical education taichung veterans general hospital taichung taiwan. 8division of rheumatology and immunology department of internal medicine national taiwan university hospital taipei taiwan. 9college of medicine national taiwan university hospital taipei taiwan. 10division of rheumatology allergy and immunology chang gung memorial hospital taoyuan taiwan. 11chang gung university taoyuan taiwan. 12division of rheumatology allergy and immunology kaohsiung chang gung memorial hospital kaohsiung taiwan. 13division of allergy immunology and rheumatology kaohsiung veterans general hospital kaohsiung taiwan. 14department of postbaccalaureate medicine college of medicine national chung shan university kaohsiung taiwan. 15division of allergy immunology and rheumatology triservice general hospital taipei taiwan. 16college of medicine national defense medical university taipei taiwan. 17rheumatology and immunology center china medical university hospital taichung taiwan. 18college of medicine china medical university taichung taiwan. 19institute of medicine chung shan medical university taichung taiwan. secondary hypogammaglobulinemia shg is characterized by reduced serum immunoglobulin ig levels and is typically caused by immunosuppressive therapy or certain diseases. patients with systemic autoimmune rheumatic diseases sards and hematological malignancies are particularly susceptible to developing shg due to underlying diseases and the use of immunosuppressive medications such as bcelltargeted agents. consequently shg significantly contributes to increased risks of severe infections and mortality in sards patients. considering the lack of a unified strategy for managing shg the taiwan college of rheumatology tcr aimed to formulate consensus recommendations for the screening diagnosis and management of shg. these recommendations were developed based on emerging evidence during a facetoface meeting of the tcr committee nine immunologists and rheumatologists and utilizing the modified delphi process. this meeting involved a comprehensive review of the current evidence using the grading of recommendations assessment development and evaluation grade methodology. thirteen consensus recommendations were developed to emphasize the importance of early detection and optimal treatment of shg. furthermore effective prevention of infections through risk assessment alongside timely and regular monitoring of igg levels was highlighted. the recommendations also included antiinfective therapies and intravenous ig replacement offering valuable guidance to rheumatologists in managing shg. this consensus will be regularly updated as newer evidence emerges. 2025 the authors. international journal of rheumatic diseases published by asia pacific league of associations for rheumatology and john wiley sons australia ltd. doi 10.11111756185x.70310 pmcid pmc12169084 pmid 40522036 indexed for medline conflict of interest statement the authors declare no conflicts of interest.",
    "6. patient educ couns. 2025 sep138109223. doi 10.1016j.pec.2025.109223. epub 2025 jun 9. my child needs a chance and a choice to talk about their pain parents experiences and perspectives of pain communication in paediatric rheumatology. lee rr1 edwards j2 mountain dc3 mcdonagh je4 connelly m5 palermo t6 peters s2. author information 1centre for epidemiology centre for musculoskeletal research division of musculoskeletal and dermatological sciences faculty of biology medicine and health university of manchester manchester academic health science centre manchester uk national institute for health research biomedical research centre manchester university hospital nhs trust manchester uk. electronic address rebecca.lee4manchester.ac.uk. 2manchester centre for health psychology division of psychology and mental health university of manchester manchester uk. 3centre for epidemiology centre for musculoskeletal research division of musculoskeletal and dermatological sciences faculty of biology medicine and health university of manchester manchester academic health science centre manchester uk national institute for health research biomedical research centre manchester university hospital nhs trust manchester uk manchester centre for health psychology division of psychology and mental health university of manchester manchester uk. 4centre for epidemiology centre for musculoskeletal research division of musculoskeletal and dermatological sciences faculty of biology medicine and health university of manchester manchester academic health science centre manchester uk national institute for health research biomedical research centre manchester university hospital nhs trust manchester uk. 5division of developmental and behavioral health childrens mercy kansas city 2401 gillham road kansas city usa. 6center for child health behavior and development seattle childrens research institute seattle wa usa. objective to investigate parents experiences and perspectives about pain communication with healthcare professionals in paediatric rheumatology. methods data were collected using semistructured telephone interviews with parents of childrenadolescents recruited from three uk tertiary paediatric rheumatology centres. a framework analysis was used to characterise parents experiences and perspectives. results eighteen parents participated. their children had a median age of 13 years sd 3.16 years range 616 years 55 male with diagnoses of chronic primary pain e.g. ehlers danlos syndromehypermobility and chronic secondary pain e.g. juvenile idiopathic arthritis. data were organised into four themes 1 parents active role in pain communication 2 building blocks of effective pain communication 3 stark realities of pain communication and 4 purpose for prioritising pain communication. parents discussed their role in advocating for their child and encouraging their child to communicate about their pain. parents reported experiences of unsatisfactory pain management advice being provided and frequent experiences of their childs pain being dismissed by healthcare professionals. conclusion findings emphasise several advantages of involving parents in communication about their childs pain as well as a range of challenges in pain communication with healthcare professionals from parent perspectives. practice implications these findings inform recommendations to facilitate more effective pain communication approaches which include parents in the future. copyright 2025 the authors. published by elsevier b.v. all rights reserved. doi 10.1016j.pec.2025.109223 pmid 40517516 indexed for medline conflict of interest statement declaration of competing interest the authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.",
    "7. nutrients. 2025 may 3117111893. doi 10.3390nu17111893. vitamin d levels in patients presenting to a rheumatology clinic in germany associations with patient characteristics and season. feuchtenberger m12 kovacs ms1 nigg a1 schfer a23. author information 1rheumatologie mvz med bayern ost 84489 burghausen germany. 2medizinische klinik und poliklinik ii university hospital wrzburg 97080 wrzburg germany. 3diabetes zentrum mergentheim 97980 bad mergentheim germany. background high rates of vitamin d deficiency have been reported in populationbased studies including those conducted in germany. the goal of this study was to evaluate vitamin d levels and associated factors in a clinical cohort of german patients presenting to a rheumatology clinic. methods we conducted a retrospective observational study of electronic health record data from patients presenting to a rheumatology clinic in southern germany. data included demographic characteristics and vitamin d levels as measured by the elecsys vitamin d total iii assay roche. associations between vitamin d levels and patient characteristics were evaluated by pearson correlation analyses ttests and multiple regression analyses. we also explored seasonal changes. results a total of 4979 patients were included 3230 64.9 were female and the mean standard deviation sd age was 53.6 15.2 years. the mean sd vitamin d level was 27.4 14.0 ngml range 3240 ngml. overall 1540 30.9 had vitamin d levels in the deficient range 20 ngml 1774 35.6 had sufficient vitamin d 20 to 30 ngml 1597 32.1 had optimal vitamin d levels 30 to 70 ngml and 68 1.4 had levels 70 ngml. lower vitamin d levels were significantly associated with younger age male sex and higher body mass index. mean levels were significantly lower during winter months and the percentages of patients with vitamin d deficiency were higher. conclusions our data indicate that low levels of vitamin d are common in clinical cohorts particularly in men younger adults overweight individuals and during winter months. patient education andor supplementation may help to address this issue and potentially improve patient health. doi 10.3390nu17111893 pmcid pmc12158044 pmid 40507162 indexed for medline conflict of interest statement authors m.s.k. a.n. and m.f. were employed by the company mvz med bayern ost. a.s. reports personal fees from amgen astrazeneca novo nordisk pharma gmbh outside the submitted work. m.f. reports personal fees from abbvie personal fees from roche and personal fees from ucb outside of the submitted work. m.s.k. and a.n. declare no disclosures relevant to this manuscript.",
    "8. lancet child adolesc health. 2025 jul97508518. doi 10.1016s2352464225001221. treatment of polyarticular juvenile idiopathic arthritis in latin america recommendations from the panamerican league of associations for rheumatology. gutirrezsurez r1 appenzeller s2 silva ca3 fonseca ar4 morel z5 eraso r6 franco l7 cuttica rj8 zavaler maf9 cruz kvj10 barzola ml11 talesnik e12 fuentes ef13 estrella ai9 jurado rm14 rivera ila15 zuccardi pg16 nogus bhl17 tineo cr18 herrera cn19 caffa jac14 ringer a20 stieben lar20 brun lr20 zcaro nmm21 fernndezvila dg22 brance ml20 espada g11 pan american league of associations for rheumatology panlar. author information 1hospital para el nio instituto materno infantil del estado de mxico toluca mxico hospital shriners para nios mxico city mxico. electronic address raul.gutierrez.suarez.reepgmail.com. 2university of campinas sao paulo brazil. 3hospital das clnicas da faculdade de medicina da universidade de so paulo so paulo brazil. 4universidade federal do rio de janeiro rio de janeiro brazil. 5universidad nacional de asuncin san lorenzo paraguay. 6hospital pablo tobn uribe antioquia colombia universidad de antioquia antioquia colombia. 7hospital infantil municipal crdoba hospital privado universitario crdoba argentina. 8hospital general de nios pedro de elizalde buenos aires argentina. 9instituto nacional de salud del nio lima per. 10universidad el bosque clnica peditrica clnica colsanitas bogot colombia. 11hospital de nios ricardo gutirrez universidad de buenos aires buenos aires argentina. 12pontificia universidad catlica de chile metropolitana de santiago chile. 13hospital infantil de mxico federico gomez mxico city mxico. 14centro hospitalario pereira rossell montevideo uruguay. 15san juan city hospital san juan puerto rico. 16fundacin cardioinfantil de bogot bogot colombia. 17hospital de los valles pichincha ecuador. 18hospital cabral y bez santiago dominican republic hospital infantil arturo grulln torino santiago dominican republic. 19hospital roberto gilbert elizalde guayaquil guayas ecuador. 20rosario national university santa fe argentina. 21hospital italiano de buenos aires buenos aires argentina. 22pontificia universidad javeriana bogot colombia. to develop evidencebased treatment guidelines for nonsystemic polyarticularjuvenile idiopathic arthritis polyjia in latin america endorsed by the panamerican league of associations for rheumatology panlar a panel of paediatric rheumatologists from latin america formulated clinically relevant questions regarding polyarthritis treatment using the population intervention comparator and outcome pico format. following the grading of recommendations assessment development and evaluation methodology a team of methodologists conducted a systematic literature review extracted and summarised intervention effect estimates and assessed the quality of evidence. the panel of paediatric rheumatologists voted on each pico question and formulated recommendations requiring a consensus of at least 70 amongst the voting members. eight recommendations and one expert opinion statement were developed. for newly diagnosed polyjia or those with minimal disease activity the use of nonsteroidal antiinflammatory drugs as adjuvant therapy along with a nonbiological diseasemodifying antirheumatic drug nbdmard is recommended. for children and young people achieving an inactive disease state continuation of nbdmard treatment for at least 12 months postremission is advised. in cases of methotrexate intolerance contraindications limited availability or nonresponse leflunomide could be used as an alternative. for children and young people with high disease activity or poor prognostic factors the addition of a biological diseasemodifying antirheumatic drug bdmard is recommended. triple therapy with methotrexate sulfasalazine and hydroxychloroquine can be considered when bdmards are not available. lowdose shortterm corticosteroid use is also recommended. the first panlar polyjia treatment guidelines offer evidencebased recommendations to support healthcare providers in the management of polyjia in latin america. copyright 2025 elsevier ltd. all rights reserved including those for text and data mining ai training and similar technologies. doi 10.1016s2352464225001221 pmid 40506199 indexed for medline conflict of interest statement declarations of interest these guidelines were endorsed by panlar. dgfa mlb and nmmz are part of panlar committees. the methodologists ar lars and lrb received support from panlar. in addition re reports speaker fees from novartis abbvie pfizer and roche. pgz reports speaker fees from novartis and alexion. kj reports speaker fees from abbvie pfizer and alexion. crt reports speakers fees from novartis janssen and astrazeneca. only panlar committee members who are named as authors were involved in the writing of the manuscript. panlar approved the decision of submitting the guidelines for publication.",
    "9. adv rheumatol. 2025 jun 1165126. doi 10.1186s42358025004592. a reallife study of juvenile idiopathic arthritis from two brazilian referral centers for pediatric rheumatology. terrazas aml1 surez rg2 campos rt3 len ca4 aikawa ne3 fernandez jd4 dantas ml4 silva ca3 clemente g4 terreri mt4. author information 1paediatric rheumatology unit paediatrics department universidade federal de sao paulo bacelar street 173 12 floor sao paulo sp 04026000 brazil. anita051287hotmail.com. 2shriners hospital for children mexico city mxico. 3childrens institute faculdade de medicina hospital das clnicas hcfmusp universidade de sao paulo sao paulo brazil. 4paediatric rheumatology unit paediatrics department universidade federal de sao paulo bacelar street 173 12 floor sao paulo sp 04026000 brazil. background juvenile idiopathic arthritis jia is the most common rheumatic disease in childhood but its outcomes are still difficult to determine. we aimed to obtain outcome measurements of disease activity functional capacity disease damage and therapeutic response at oneyear followup study on a reallife basis. methods an observational jia cohort from two referral centers for pediatric rheumatology in brazil pediatric rheumatology centers was carried out over a period of one year. clinimetric validated outcome measurements were applied over four visits. multivariable logistic regression was performed to evaluate baseline variables associated with the following outcomes after one year of followup disease activity minimal disease activity mda disease flare remission on medication and remission off medication. results a total of 127 patients were included in the study. eightythree 65.4 were females and median time to diagnosis was 6.0 months. jadas71 and chaq improved during followup mean vbaseline 7.05 9.3 vs. v52 3.52 8.4 0 0.5 vs. 0.14 0.4 p 0.001 respectively as well as jiaacr 30 50 70 and 90 vbaseline 79.8 vs. v52 88.8 71.4 vs. 84.1 59.7 vs. 77.6 49.6 vs. 69.2 p 0.05 respectively. inactive disease was present in 33 of patients at baseline and in 67.9 at v52 p 0.001. remission on medication remission off medication and mda were present in 46 11 and 80.6 of patients at v52 respectively. extraarticular and articular damage were not common at baseline 0.3 0.7 and 1.1 3.4 respectively and did not decrease significantly during the period of the study. the presence of active joints 46101 45.5 at baseline reduced the chance of the patient achieving remission off medication at the last visit by 84 or 0.16 ci 95 from 0.03 to 0.91 p 0.039. conclusion this study showed improvement in clinimetric outcome measurements and therapeutic responses in an inception cohort of jia patients. the presence of active joints at baseline is related to not achieving remission at last visit. longterm prospective and multicenter studies are needed to better assess the outcome of jia and the differences among jia subtypes. 2025. the authors. doi 10.1186s42358025004592 pmid 40500805 indexed for medline conflict of interest statement declarations. ethics approval and consent to participate the study protocol was approved by the institutional review board of universidade federal de so paulo caae 27544919.1.0000.5505 and research ethics committee childrens institute hospital das clnicas hcfmusp faculdade de medicina universidade de sao paulo caae 27544919.1.2008.0068. all participants and their legal guardians when appropriate provided written informed consent. all procedures were performed in accordance with the 1964 declaration of helsinki and its later amendments or comparable ethical standards. consent for publication publication consent was acquired on the original consent form. footnotes not applicable. competing interests ana mara loroo terrazas gleice clemente ral gutirrez surez reinan tavares campos claudio arnaldo len nadia emi aikawa jade dib fernandez mayra lisyer dantas clvis artur silva maria teresa terreri declare that they have no conflict of interest.",
    "10. j bodyw mov ther. 2025 sep43124129. doi 10.1016j.jbmt.2025.04.019. epub 2025 apr 17. are rheumatology field professionals scientifically prepared to rehabilitate using exercise a crosssectional survey. cavalcanti bh1 cavalcanti rr1 de souza mc2 pontessilva a3. author information 1federal university of rio grande do norte faculty of health sciences of trairi ufrnfacisa postgraduate program in rehabilitation sciences santa cruz rn brazil. 2federal university of rio grande do norte department of physical therapy natal rn brazil. 3federal university of so carlos department of physical therapy so carlos sp brazil. electronic address contato.andrepsilvagmail.com. objective to assess rheumatology professionals knowledge about the physical exercise. methods a crosssectional study. we included bachelors of physical education and physical therapists because they are professionals who use exercise as a therapeutic intervention for musculoskeletal rehabilitation. we assessed their knowledge using structured questions based on the eular. we used the chisquared test 5 to compare the number of correct and incorrect answers and calculated the effect size w value by dividing the chisquared value by the number of scores and taking the square root small w 0.10 medium w 0.30 and large w 0.50. results the sample of this study consists of 116 health professionals with a mean age of 34.43 8.71 years. the majority are women and physical therapists. regarding the health professionals knowledge about the use of exercise in patients with musculoskeletal disorders we observed a significant number of incorrect answers p 0.001 to the eular questions. clinically the large effect size w 0.5 for the number of errors indicated a worrying situation for the musculoskeletal rehabilitation scenario. conclusion bachelors of physical education as well as physical therapists are not scientifically prepared to rehabilitate people with rheumatic and musculoskeletal diseases through physical exercise. copyright 2025 elsevier ltd. all rights reserved. doi 10.1016j.jbmt.2025.04.019 pmid 40483112 indexed for medline conflict of interest statement declaration of competing interest the authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.",
    "11. clin exp med. 2025 jun 6251189. doi 10.1007s10238025017179. from myth to bedside a scoping review of the applications of the chimeric antigen receptor in rheumatology. niotorres d12 quintanalpez g3456 salguero g7 reumavance group. author information 1department of internal medicine school of medicine universidad nacional de colombia bogota colombia. dianinotounal.edu.co. 2departamento de medicina interna facultad de medicina universidad nacional de colombia carrera 30 no. 4503 edificio 471 111321 bogota colombia. dianinotounal.edu.co. 3department of internal medicine school of medicine universidad nacional de colombia bogota colombia. 4department of internal medicine school of medicine universidad de los andes bogota colombia. 5rheumatology section department of internal medicine fundacin santa fe de bogot university hospital bogota colombia. 6departamento de medicina interna facultad de medicina universidad nacional de colombia carrera 30 no. 4503 edificio 471 111321 bogota colombia. 7advanced therapies unit instituto distrital de ciencia biotecnologa e innovacin en saludidcbis 111611 bogota colombia. chimeric antigen receptor car based therapies are promising in systemic autoimmune rheumatic disease sard according to recent case reports. to establish the state of the art of the applications of car therapies in rheumatology pubmed embase lilacs as well as clinical trial registries were searched. any type of original article that reported the use of these therapies in patients with sard was included. fortyeight studies were included from databases. ninetyfive ongoing trials were included from clinical trials registries. the most used type of car was a cart against cd19 showing good preliminary results. other targets used were bcma pd1 a modified hla and citrullinated peptides among others. the use of other cell types such as natural killer and regulatory t cells was also found. carbased therapies in rheumatology are in an early stage of development but with promising results. there has been a notable growth in human patients treated with this intervention in the last 2 years. this and other innovative designs will offer a wide range of new therapeutic possibilities. results of ongoing clinical trials are needed to establish their efficacy and safety in sard. 2025. the authors. doi 10.1007s10238025017179 pmcid pmc12144057 pmid 40481370 indexed for medline conflict of interest statement declarations. conflict of interest the authors declare no competing interests. consent to participate not applicable. ethical approval this is a review article. the research ethics committee of the national university of colombia faculty of medicine has confirmed that no ethical approval is required.",
    "12. pediatrics. 2025 jul 11561e2024069821. doi 10.1542peds.2024069821. essential areas of knowledge in rheumatology for pediatric residents a modified delphi study. shalen j1 austenfeld e2 vater m3 curran m4 hayward k5 mehta j6 gillispietaylor m7 carra medical education working group. author information 1division of allergy immunology and rheumatology department of pediatrics johns hopkins university school of medicine baltimore maryland. 2division of rheumatology department of pediatrics medical college of wisconsin milwaukee wisconsin. 3division of rheumatology cincinnati childrens hospital medical center and department of pediatrics university of cincinnati college of medicine cincinnati ohio. 4division of rheumatology department of pediatrics university of colorado school of medicine aurora colorado. 5division of rheumatology department of pediatrics seattle childrens hospital and university of washington school of medicine seattle washington. 6division of rheumatology department of pediatrics university of pennsylvania perelman school of medicine and childrens hospital of philadelphia philadelphia pennsylvania. 7division of rheumatology department of pediatrics huffington department of education innovation and technology baylor college of medicine texas childrens hospital houston texas. background graduating pediatric residents need practical knowledge to recognize provide initial management and appropriately triage patients with childhood rheumatologic diseases crds. the pediatric rheumatology workforce shortage and lack of focused american board of pediatrics rheumatology content specifications lead to challenges in the adequate education of trainees. the purpose of this study was to define essential knowledge areas in rheumatology for pediatric residents. methods a literature search was performed to identify resources pertinent to resident education in pediatric rheumatology. results were used to inform items on a survey asking how important is it for graduating pediatric residents to demonstrate competency in each of these rheumatologyrelated activities stakeholders in rheumatologyrelated pediatric resident education were invited to participate in a modified delphi process. subsequent surveys were created iteratively based on their responses. results twentyone panelists from diverse geographic regions and specialties completed 2 rounds of surveys with a 100 completion rate. analysis yielded 107 items those rated by 70 of respondents as very important were categorized as essential n 54 47.7 and those rated by 70 of respondents as either very important or somewhat important were categorized as recommended n 55 52.3. conclusions broad content specifications are insufficient to prepare graduating pediatric residents to address crds in practice. given the pediatric rheumatology workforce shortage access to an expanded standardized list of critical rheumatologyrelated competencies is essential to better prepare graduating pediatric residents to evaluate patients with crds. these competencies should drive curriculum design to enhance pediatric resident education. copyright 2025 by the american academy of pediatrics. doi 10.1542peds.2024069821 pmid 40473248 indexed for medline",
    "13. j orthop surg res. 2025 jul 17201672. doi 10.1186s1301802506052z. clinical efficacy and radiological changes of proximal fibular osteotomy for medial compartment knee osteoarthritis a systematic review and metaanalysis. jiang y1 li j2 zhang l3 jia x1 wang t1 zhao x4 chen j5 xu k6. author information 1knee preservation center the affiliated hospital of qingdao university qingdao shandong 266000 china. 2department of endocrine affiliated hospital of qingdao university qingdao shandong 266000 china. 3department of abdominal ultrasound affiliated hospital of qingdao university qingdao shandong 266000 china. 4department of sports medicine the affiliated hospital of qingdao university qingdao shandong 266000 china. 5knee preservation center the affiliated hospital of qingdao university qingdao shandong 266000 china. chenjinli2000163.com. 6knee preservation center the affiliated hospital of qingdao university qingdao shandong 266000 china. 1213218702qq.com. contributed equally objective we aimed to analyze the clinical efficacy safety and radiological changes of proximal fibular osteotomy pfo for medial compartment knee osteoarthritis mkoa. methods since the establishment of the databases we searched all studies involving proximal fibular osteotomy in pubmed proquest scopus and web of science. the outcomes of interest were visual analog scale vas knee function scores radiological results and complication rates. casecontrol studies were assessed using the newcastleottawa scale and randomized controlled trials were independently evaluated using the cochrane collaborations assessment tool. heterogeneity was tested using i and a fixed or randomeffects model was selected for metaanalysis based on the heterogeneity results. of the 21 studies included 17 were casecontrol studies and 4 were rcts. results a total of 21 studies including 1006 knees were included in the metaanalysis. pfo can effectively alleviate the most troubling pain for patients vas mean difference md 4.25 5.51 3.00 and significantly improve postoperative knee function hedges g 2.41 1.353.47. moreover due to the minimal surgical trauma the incidence of postoperative complications is low with sensory abnormalities of the common peroneal nerve being the most common adverse event 5.93 95 ci 2.1511.25 followed by common peroneal nerve palsy 2.25 95 ci 0.146.14 fracture 0.56 95 ci 01.74 and only two cases of infection were reported in all included studies both of which recovered within half a year. in addition pfo can effectively improve the radiological outcomes with an increase in hka md 1.73 0.33 3.13 a decrease in fta md 3.83 4.05 3.62 an increase in knee joint space md 2.66 mm2.38 2.94 and an increase in the ratio of medial to lateral knee joint space md 0.16 0.15 0.18. conclusion in the field of mkoa treatment pfo has shown a promising prospect. the clinical function scores and radiological assessments improved after pfo in this metaanalysis indicating that this surgical method can significantly improve patients symptoms correct the varus deformity of the lower limb alignment and is safe. however it must be pointed out that the quality of evidence supporting this conclusion is still low and radiological studies are relatively few. therefore future studies need to be conducted in more diverse patient populations incorporating more radiological indicators and providing higherquality clinical evidence. 2025. the authors. doi 10.1186s1301802506052z pmid 40676619 indexed for medline conflict of interest statement declarations. ethical approval and consent to participate this is a metaanalysis so ethics approval is not applicable. competing interests the authors declare no competing interests.",
    "14. sci rep. 2025 jul 1715125980. doi 10.1038s41598025112500. efficacy and safety of latilactobacillus sakei lbp12 in patients with knee osteoarthritis an exploratory randomized doubleblind placebocontrolled clinical trial. shine bk1 li q1 song m2 song k2 shim j2 han sh3. author information 1department of family medicine college of medicine donga university 26 daesingongwonro seogu busan 49201 republic of korea. 2rd center liscure biosciences inc. seongnam republic of korea. 3department of family medicine college of medicine donga university 26 daesingongwonro seogu busan 49201 republic of korea. handsomdrhanmail.net. contributed equally knee osteoarthritis oa is a prevalent degenerative joint disease among middleaged and older adults leading to chronic pain functional limitations and decreased quality of life. while probiotics have shown antiinflammatory potential in preclinical studies their therapeutic role in oa has not been well established in human research. this exploratory randomized controlled trial rct aimed to evaluate the efficacy and safety of latilactobacillus sakei lbp12 in improving knee oa symptoms. in this randomized doubleblind placebocontrolled trial 100 participants aged 4075 years with chronic knee pain were assigned to receive either lbp12 350 mgday 10 billion cfu or placebo for 12 weeks. the primary outcome was the change in western ontario and mcmaster universities osteoarthritis index womac scores. secondary outcomes included visual analog scale vas scores for pain inflammatory markers crp esr il1 il6 tnf cartilage degradation biomarkers comp joint space width and healthrelated quality of life eq5d5l. safety was evaluated using laboratory tests and vital signs. after 12 weeks the lbp12 group showed significantly greater improvements in womac total scores and vas pain scores compared to the placebo group. all three womac subdomainspain stiffness and physical functionshowed consistent reductions. inflammatory cytokines particularly il1 were significantly reduced in the lbp12 group. quality of life also improved significantly. no adverse events or clinically meaningful abnormalities in laboratory values were observed. this exploratory rct suggests that daily supplementation with lbp12 is safe and may offer potential benefits in reducing knee pain and improving physical function and quality of life in individuals with knee oa. further largescale and longterm rcts are needed to confirm these findings and elucidate the underlying mechanisms. 2025. the authors. doi 10.1038s41598025112500 pmid 40676109 indexed for medline conflict of interest statement declarations. competing interests the authors declare no competing interests. ethical approval this study was performed in accordance with the declaration of helsinki and approved by the institutional review board irb of the donga university hospital institutional review board dauhirbexp23187 11 sept. 2024. informed consent informed consent was obtained from all the participants before their inclusion in this study.",
    "15. bmj open. 2025 jul 17157e099827. doi 10.1136bmjopen2025099827. diverse diagnostic and management approaches for acute rheumatic fever in australia and new zealand findings of a prospective clinical study. peiris r1 webb r234 bennett j56 yan j17 francis jr1 remenyi b7 chan mow f2 burgess r8 wilson nj3 stanley a3 francis l7 holloway r3 westbury r3 lawrence s2 hernandezgomez y7 broadhurst d9 moreland nj6 mcgregor r6 motteram c8 pearson g8 mayo m1 ralph ap107 carapetis jr811. author information 1global and tropical health menzies school of health research tiwi northern territory australia. 2kidz first childrens hospital and community health centre for youth health auckland new zealand. 3starship childrens health auckland auckland new zealand. 4department of paediatrics child and youth health the university of auckland auckland new zealand. 5department of public health university of otago wellington new zealand. 6department of molecular medicine and pathology the university of auckland school of medical sciences auckland new zealand. 7royal darwin hospital casuarina northern territory australia. 8the kids research institute australia nedlands western australia australia. 9school of science edith cowan university perth western australia australia. 10global and tropical health menzies school of health research tiwi northern territory australia anna.ralphmenzies.edu.au. 11perth childrens hospital nedlands western australia australia. contributed equally objectives to describe diagnostic and management characteristics of acute rheumatic fever arf among participants in the searching for a technologydriven acute rheumatic fever test study in order to answer clinical questions and determine epidemiological and practice differences in different settings. design multisite prospective cohort study. setting one hospital in northern australia and two hospitals in new zealand 20182021. participants 143 episodes of definite probable or possible arf among 141 participants median age 10 years range 523 98 indigenous. primary and secondary outcome measures participant characteristics clinical biochemical and echocardiographic data were explored using descriptive data. associations with length of stay were determined using multivariable regression analysis. results arf presentations were heterogeneous with the most common arf phenotype in 19 of cases being carditis with joint manifestations polyarthritis monarthritis or polyarthralgia fever and pr prolongation. the total proportion of children with carditis was 61. australian compared with new zealand participants more commonly had arf recurrence 22 vs 0 underlying rhd 48 vs 0 possibleprobable arf 23 vs 9 and were underweight 64 vs 16. erythrocyte sedimentation rate esr provided an incremental diagnostic yield of 21 compared with c reactive protein. no instances of rhd were diagnosed among participants in new zealand. positive throat group a streptococcus culture was more common in new zealand than in australian participants 69 vs 3. children often required prolonged hospitalisation with median hospital lengthofstay being 7 days range 266. significant predictors for length of stay in a multivariable regression model were valve disease adjusted or aor 1.56 95 ci 1.23 to 1.98 p0.001 requirement for corticosteroids aor 1.99 95 ci 1.22 to 3.26 p0.007 and higher esr aor 1.4 95 ci 1.17 to 1.67 p0.001. conclusions this study provides new knowledge on arf characteristics and management and highlights international variation in diagnostic and management practice. differing approaches need to be aligned. meanwhile locally specific information can help guide patient expectations after arf diagnosis. authors or their employers 2025. reuse permitted under cc by. published by bmj group. doi 10.1136bmjopen2025099827 pmid 40675648 indexed for medline conflict of interest statement competing interests none declared.",
    "16. jbjs case connect. 2025 jul 17153. doi 10.2106jbjs.cc.25.00143. ecollection 2025 jul 1. distal tibial slipped epiphysis in stickler syndrome a case report. nahm nj12 georgiadis ag12 dahl mt12. author information 1gillette childrens specialty healthcare saint paul minnesota. 2department of orthopaedic surgery university of minnesota minneapolis minnesota. case stickler syndrome is a collagen disorder associated with hypermobility and juvenile osteoarthritis in multiple joints. this report presents a 12yearold adolescent boy with stickler syndrome presenting with bilateral ankle pain. he had bilateral distal tibial recurvatumvalgus deformity and distal tibial slipped epiphysis dtse. he underwent osteotomy along the true plane of deformity and internal fixation. at the latest followup he had decreased pain and improved clinical and radiographic alignment. conclusions dtse is a rare condition contributing to ankle deformity. previously reported in renal osteodystrophy and myelomeningocele dtse is reported herein for the first time in association with stickler syndrome. copyright 2025 by the journal of bone and joint surgery incorporated. doi 10.2106jbjs.cc.25.00143 pmid 40674469 indexed for medline conflict of interest statement disclosure the disclosure of potential conflicts of interest forms are provided with the online version of the article httplinks.lww.comjbjsccc655.",
    "17. neurochem res. 2025 jul 17504234. doi 10.1007s11064025044878. ana12 targets and inhibits bdnftrkb signaling to alleviate pain behaviors in rheumatoid arthritis mice. yuan m1 zhang l1 zheng y1 xie m2. author information 1school of pharmacy school of basic medical sciences hubei university of science and technology xianning china. 2school of pharmacy school of basic medical sciences hubei university of science and technology xianning china. xiemin2020a163.com. contributed equally rheumatoid arthritis ra is a chronic systemic inflammatory disease. sensitization of central pain pathways by proinflammatory mediators has been implicated in ra pain. locus coeruleus lc functions in pain pathways. brainderived neurotrophic factor bdnf participates in the modulation of nociception and pain. a mouse model of ra immunized with collageninduced arthritis cia was used for investigating the mechanisms of pain relief by administration of the tropomyosin receptor kinase b trkb receptor antagonist ana12. we measured the pain behaviors and locomotor activity and found increased pain sensitivity and locomotor deficit in ra mice ana12 treatment reduced pain behaviors and promoted locomotor function recovery. the glial activation and increased activities of bdnftrkb and mapk signal pathways were found in lc of ra mice. the components of nlrp3 inflammasome were all increased and consequently enhanced the production of proinflammatory cytokine interleukin il1. upon ana12 treatment glial cell activation was reduced bdnftrkb and mapk pathways were suppressed and the expression levels of the abovementioned proteins were reduced. finally u251 cells were conducted to further confirm the regulatory mechanisms of ana12 on inflammation. the results showed the colocalization of bdnfnlrp3il1 and gfap. ana12 treatment decreased the protein levels of bdnf trkb mapk nlrp3 and caspase1 in il1induced cells. besides ana12 treatment decreased nlrc4 and aim2 inflammasomes both in ra mice and il1induced cells. these results suggested that ana12 alleviates hyperalgesia in ra mice by inhibiting bdnftrkb signaling in lc thereby reducing glial cell activation and inflammatory cytokine release. 2025. the authors. doi 10.1007s11064025044878 pmid 40673956 indexed for medline conflict of interest statement declarations. ethical approval the animal experiment was approved by the ethics committee of animal experimentation at hubei university of science and technology approval no. 202303028. competing interests the authors declare no competing interests.",
    "18. rheumatol int. 2025 jul 17458174. doi 10.1007s00296025059134. minimal seasonal variation in disease parameters of axial spondyloarthritis a registerbased study. onkamo e1 sundstrm b23 wahlin b4. author information 1department of public health and clinical medicinerheumatology ume university ume 901 87 sweden. emma.onkamoumu.se. 2centre for research and development uppsala universityregion gvleborg gvle 801 88 sweden. 3department of public health and caring sciencesgeneral practice uppsala university uppsala 751 22 sweden. 4department of public health and clinical medicinerheumatology ume university ume 901 87 sweden. bengt.wahlinumu.se. objectives axial spondyloarthritis axspa displays varying disease activity over time. however few studies have examined the association between disease activity and seasonal differences and consequently evidence of a seasonality in disease activity in axspa is limited. we therefore aimed to study the variation in measures of disease activity perceived wellbeing and functional ability including both patientreported and objective measures throughout the year and their relationship with seasons. methods objective and patientreported disease parameters from 44 987 assessments on 5197 individuals were retrieved from the swedish rheumatology quality register. the variation in different measures of disease activity over the year was examined using generalized additive models with cyclic cubic splines. results patient reported and objective measures of disease were found to vary congruently over the year with a trend of decreased disease parameters in the spring. mean crp values showed a statistically significant variation throughout the year with highest in july 7.35 mgl and lowest in march 6.88 mgl. significant seasonal variation was also seen in basdai range of mean values 3.673.72 basfi 2.792.87 and basmi 3.263.31 with highest values in late summer beginning of fall or in the fall respectively. in subgroup analysis significant variation was only seen in subjects with a disease duration of more than 10 years. conclusion although a statistically significant seasonal variation in disease parameters was found the absolute variation was close to none and may therefore be clinically irrelevant. 2025. the authors. doi 10.1007s00296025059134 pmid 40673910 indexed for medline conflict of interest statement declarations. conflict of interest authors have no conflict of interest to declare.",
    "19. nan fang yi ke da xue xue bao. 2025 jul 2045713891396. doi 10.12122j.issn.16734254.2025.07.05. qianggu kangshu formula attenuates osteoclast differentiation in rheumatoid arthritis by inhibiting the hif1bnip3 autophagy signaling pathway. article in chinese abstract available in chinese from the publisher li w12 jiang l3 zhang z12 chen d1 bao z12 huang l4 yuan l12. author information 1hubei provincial key laboratory of rheumatic disease occurrence and intervention hubei minzu university enshi 445000 china. 2health science center hubei minzu university enshi 445000 china. 3department of general medicine shizhu county hospital of traditional chinese medicine chongqing 409100 china. 4department of rheumatology enshi huiyi hospital of rheumatic diseases enshi 445000 china. objectives to investigate the effect of qianggu kangshu formula qgksf for alleviating osteoclast differentiation in rheumatoid arthritis and the underlying mechanism. methods raw264.7 cells cultured under hypoxic conditions were treated with rankl to induce osteoclast differentiation and incubated with normal rat serum or sera from rats medicated with methotrexate mtx or qgksf at low and high doses. cell viability trappositive multinucleated cells and factin ring formation in the treated cells were assessed with cck8 assay trap staining and phalloidin staining respectively. autophagy and autophagosomes in the cells were observed with mdc staining and transmission electron microscopy. elisa was used to measure il6 and tnf levels in the culture supernatant and the expressions of hif1 bnip3 bcl2 beclin1 lc3i lc3ii p62 and trap mrnas and proteins were analyzed using rtqpcr and western blotting. results in hypoxia and ranklinduced raw264.7 cells treated with normal rat serum significant increments of trappositive cells and factin ring formation were observed with an enhanced autophagic fluorescence intensity and increased autophagosomes. treatment of the induced cells with rat sera medicated with mtx and low and highdose qgksf obviously reduced the trappositive cells factin rings and autophagosomes as well as the autophagic fluorescence intensity. rankl treatment significantly increased il6 and tnf levels in raw264.7 cells which were obviously decreased by treatment with mtx and qgksfmedicated sera. rankl also significantly increased the mrna and protein expression levels of hif1 bnip3 bcl2 beclin1 lc3 and trap and lowered p62 expressions and these changes were effectively reversed by treatment with mtx and qgksfmedicated sera. conclusions qgksf attenuates ranklinduced osteoclast differentiation in hypoxic raw264.7 cells by inhibiting the hif1bnip3 autophagy signaling pathway suggesting its potential for treatment of bone destruction in rheumatoid arthritis. publisher qgksfhif1bnip3 raw264.7ranklmtxqgksfqgksflqgksfqgksfhcck8traptrapfmdcelisail6tnfwestern blottinghif1bnip3bcl2beclin1lc3lc3p62traprtqpcrhif1bnip3bcl2beclin1lc3p62trapmrna trapfp0.001mtxqgksflqgksfhtrapfp0.01il6tnfp0.001mtxqgksfil6tnfp0.001hif1bnip3bcl2beclin1lc3trapmrnap62mrnap0.01mtxqgksfhif1bnip3bcl2beclin1lc3trapmrnap62mrnap0.05 qgksfhif1bnip3ranklraw264.7ra. doi 10.12122j.issn.16734254.2025.07.05 pmcid pmc12268912 pmid 40673301 indexed for medline conflict of interest statement the authors declare no competing interests.",
    "20. peerj. 2025 jul 1413e19708. doi 10.7717peerj.19708. ecollection 2025. mapkerk signaling pathway in rheumatoid arthritis mechanisms and therapeutic potential. xie j12 sun s1 li q1 chen y3 huang l3 wang d3 wang y3. author information 1state key laboratory of southwestern chinese medicine resource school of pharmacy chengdu university of traditional chinese medicine chengdu china. 2santai peoples hospital mianyang china. 3school of basic medical sciences chengdu university of traditional chinese medicine chengdu china. rheumatoid arthritis ra is a multifaced autoimmune disorder characterized by chronic joint inflammation leading to progressive disability and significantly impacting patients quality of life. despite advances in treatment finding a cure or preventing disease progression remains a major clinical challenge underscoring the urgent need for novel therapeutic strategies. among various pathways involved in the pathophysiology of ra the mitogenactivated protein kinasesextracellular regulated protein kinases mapkerk pathway is of particular importance. as the central cascade within the broader mapk signaling pathways mapkerk plays a critical role in regulating numerous physiological and pathological processes with a wellestablished and prominent involvement in ra. unlike p38 mapk and cjunnterminal kinase jnk whose role in ra have been welldocumented the specific contributions of the mapkerk pathway to ra remains comprehensively unreviewed. furthermore the mapkerk pathway does not act in isolation but interacts synergistically with other major pathways including nfb janus kinasesignal transducer and activator of transcription jakstat sonic hedgehog shh and pi3kakt which further enhance its pathological effects. this review offers a comprehensive analysis of mapkerk signaling pathway focusing on its molecular components and its contribution to ra pathophysiology. furthermore we explore the crosstalk between mapkerk and other pathways in the context of ra and evaluates the therapeutic potential of targeting this pathway with small molecule inhibitors natural compounds and biomolecules. by elucidating the mechanistic role of mapkerk in ra this article aims to highlight the pathways therapeutic relevance and provide a foundation for the developing more effective targeted therapies for ra. 2025 xie et al. doi 10.7717peerj.19708 pmcid pmc12269783 pmid 40677749 indexed for medline conflict of interest statement the authors declare that they have no competing interests.",
    "21. front immunol. 2025 jul 3161589341. doi 10.3389fimmu.2025.1589341. ecollection 2025. sglt2 inhibitors in autoimmune diseases emerging therapeutic potential and clinical challenges. luo t1 zhang l2 tu k34 li g2 su h34 gong g34 huang y34 li m34 yang x34. author information 1department of pharmacy chengdu seventh peoples hospital affiliated cancer hospital of chengdu medical college chengdu china. 2department of pharmacy sichuan provincial womans and childrens hospital the affliated womens and childrens hospital of chengdu medical college chengdu sichuan china. 3department of pharmacy the affiliated hospital southwest medical university luzhou china. 4school of pharmacy southwest medical university luzhou china. contributed equally autoimmune diseases aids are conditions where the immune system mistakenly attacks selfantigens leading to tissue and organ damage. the exact mechanisms underlying aids pathogenesis remain unclear and effective treatments are currently limited posing significant therapeutic challenges. recent studies suggest that targeting t cell immune metabolism could be a promising approach for treating aids. repurposed type 2 diabetes mellitus t2dm medications which modulate immune metabolic processes have shown potential in various inflammatory conditions. sodiumglucose cotransporter2 sglt2 inhibitors a novel class of oral antidiabetic agents not only regulate metabolic dysfunction but also offer protective effects on the heart and kidneys. emerging preclinical evidence indicates that sglt2 inhibitors possess immunomodulatory properties highlighting their potential in enhancing t cellmediated autoimmune therapy. clinical studies further validate that sglt2 inhibitors significantly reduce the risk of chronic kidney disease ckd progression in nondiabetic patient groups such as those with chronic glomerulonephritis like iga nephropathy. this review aims to evaluate current preclinical and clinical research on the impact of sglt2 inhibitors on the immune system and explore their mechanisms of action relevant to treating aids. copyright 2025 luo zhang tu li su gong huang li and yang. doi 10.3389fimmu.2025.1589341 pmcid pmc12267200 pmid 40677716 indexed for medline conflict of interest statement the authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.",
    "22. front immunol. 2025 jul 3161596935. doi 10.3389fimmu.2025.1596935. ecollection 2025. shortterm exposure to particulate matter triggers a selective alteration of plasma extracellular vesiclepackaged mirnas in a mouse model of multiple sclerosis. bonato m1 cerrato v1 dioni l2 montarolo f1 parolisi r1 bertolotto a34 bollati v2 ferrari l2 boda e1. author information 1neuroscience institute cavalieri ottolenghi nico department of neuroscience rita levimontalcini university of turin turin italy. 2epiget lab department of clinical sciences and community health university of milan milan italy. 3neuroscience institute cavalieri ottolenghi nico turin italy. 4koelliker hospital turin italy. epidemiological studies have highlighted the existence of population groups exhibiting a higher sensitivity to the impact of environmental factors such as exposure to air pollution. in these regards people with multiple sclerosis ms or predisposed to develop ms an autoimmune disorder of the central nervous system cns appear as a more vulnerable cohort to the effects of particulate matter pm exposure. here we aimed at disclosing the biological substrate of such higher vulnerability and specifically at understanding whether individuals primed to develop autoimmunity as it occurs in ms and in the experimental autoimmune encephalomyelitis eae animal model of ms respond differently to pm compared to healthy subjects. to this purpose we characterized plasmatic extracellular vesicles evs and their microrna mirna cargo in healthy and presymptomatic eae mice early after exposure to pm10 compared to unexposed healthy and eae mice. results showed that the response of eae mice to pm10 did not differ in terms of ev number or source compared to that of healthy mice. yet remarkable differences existed in the identity of deregulated evassociated mirnas which in eae mice were predicted to target several msrelevant biological processes and nervous system immune and inflammationrelated pathways possibly contributing to disease worsening. copyright 2025 bonato cerrato dioni montarolo parolisi bertolotto bollati ferrari and boda. doi 10.3389fimmu.2025.1596935 pmcid pmc12267195 pmid 40677715 indexed for medline conflict of interest statement the authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. the authors declared that they were an editorial board member of frontiers at the time of submission. this had no impact on the peer review process and the final decision.",
    "23. front immunol. 2025 jul 3161586426. doi 10.3389fimmu.2025.1586426. ecollection 2025. immune hemolytic anemia associated with the use of immune checkpoint inhibitors a scoping review. hernandezmartinez jm12 riosgarcia e1 palomarespalomares cb1 arrieta o1. author information 1thoracic oncology unit and experimental oncology laboratory instituto nacional de cancerologia de mexico incan mexico city mexico. 2secretara de ciencia humanidades tecnologa e innovacin secihtiinstituto nacional de cancerologa mexico city mexico. background immunehemolytic anemia iha is a rare immunerelated adverse event irae in cancer patients treated with immunecheckpoint inhibitors icis. although several cases of iciassociated iha have been reported few attempts have been made to collate available information. this scoping review aims to provide a comprehensive description of the clinical features of iciassociated iha. methods pubmed and web of science core collection databases were searched for articles published in english from january 2006 to january 2025 on iciassociated iha. only fulltext publications reporting the clinical characteristics of patients with iciassociated iha were included. two authors independently assessed the search results for eligibility and extracted the following information author publication year patient characteristics and iha features. results among 54 publications published between july 2014 and march 2024 92 cases of iciassociated iha were identified revealing a high proportion of cases in patients with melanoma 45.2 and nonsmallcell lung cancer 31. approximately half of the cases occurred in patients receiving icis as firstline systemic therapy with iha manifesting after a median of 3 cycles. the most frequent triggering icis were pembrolizumab 41.3 and nivolumab 26.1. a high proportion of cases involved patients with a medical history of hematolymphoid tumors 34.8 hypertension 15.2 and anemiaaiha 15.2. initial management involved ici discontinuation 94.6 highdose glucocorticoids therapy 97.8 and transfusion support 63 with treatment responses achieved in most cases 91.3. only 2 cases reported fatal outcomes. iha relapse was documented in only 7 of 23 30.4 patients who were rechallenged with an ici. conclusions to the best of our knowledge this is the largest scoping review of populationbased studies case reports and case series on iciassociated iha. the evidence reviewed suggests that patients with specific comorbidities may be at higher risk of developing iciassociated iha. in the absence of predictive tools to individually estimate the risk of this complication a list of frequently reported cooccurring conditions in cases of iciassociated iha may help select patients who could benefit from closer surveillance. copyright 2025 hernandezmartinez riosgarcia palomarespalomares and arrieta. doi 10.3389fimmu.2025.1586426 pmcid pmc12268707 pmid 40677712 indexed for medline conflict of interest statement the authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as potential conflicts of interest.",
    "24. arthritis res ther. 2025 jul 17271150. doi 10.1186s13075025036077. disease remission and sustained remission after etanercept biosimilar or originator initiation in rheumatoid arthritis an interim realworld analysis. birck mg12 boivin j12 yan l2 carrier n3 moura cs1 maksymowych wp4 boire g35 choquette d6 lukusa l1 mallinson m7 wilhelm l8 neville a1 bernatsky s910. author information 1research institute of the mcgill university health centre montreal qc canada. 2mcgill university montreal qc canada. 3centre integr universitaire de sant et de services sociaux de lestrie centre hospitalier de sherbrooke ciusss de lestriechus sherbrooke qc canada. 4university of alberta edmonton ab canada. 5universit de sherbrooke sherbrooke qc canada. 6institut de rhumatologie de montral centre hospitalier de luniversit de montral montreal qc canada. 7canadian spondylitis association and axial spondyloarthritis international federation toronto canada. 8canadian arthritis patient alliance toronto on canada. 9research institute of the mcgill university health centre montreal qc canada. sasha.bernatskymcgill.ca. 10mcgill university montreal qc canada. sasha.bernatskymcgill.ca. contributed equally background we compared time to first remission and prevalence of sustained remission in participants with rheumatoid arthritis ra initiating etanercept biosimilar etab or originator etao. methods we studied etanerceptnaive participants with ra from four canadian prospective cohorts who initiated etab or etao jan2015may2022. disease remission was determined using disease activity scales. sustained remission was defined as at least two consecutive visits in remission within the first 12 months of followup. multivariate cox regression was used to compare the probability of achieving remission between etab and etao and multivariate logistic regression was used to assess sustained remission. results we studied 150 participants with ra etab 65.3. among 125 participants not in remission at baseline the median time to first remission was 8.7 months 95 confidence intervals ci 5.212.1 in the etab group and 14.5 months 95 ci 4.718.6 in the etao group. time to first remission was similar between the groups logrank test pvalue 0.51. multivariate cox regression showed no clear difference in first remission between etab and etao adjusted hazard ratio 1.52 95 ci 0.683.39. among 125 participants with at least 12 months of followup the prevalence of sustained remission was 19.5 for etab and 21.0 for etao. in multivariate analysis we did not detect a significant difference in sustained remission between etab and etao adjusted odds ratio 1.14 95 ci 0.294.87. conclusion we did not detect clear differences in first remission and sustained remission between participants with ra initiating etab or etao. trial registration not applicable. 2025. the authors. doi 10.1186s13075025036077 pmid 40676646 indexed for medline conflict of interest statement declarations. ethics approval and consent to participate the study received approval from the mcgill university health centre research ethics board mp3720194560 and complies with the declaration of helsinki. the research ethics boards of participating institutions reviewed and approved the study protocol. all subjects provided written informed consent and authorization to share their data through their respective institutions prior to participating the rheumatoid arthritis pharmacovigilance program and outcomes research in therapeutics rapport university of alberta research ethics board pro00064218 the rhumadata registry institut de rhumatologie de montral institutional review board services irb00005290 biobanque de pathologies et perturbations immunes et inflammatoires centre de recherche du chus crchus centre intgr universitaire de sant et de services sociaux de lestriecentre hospitalier de sherbrooke ciusss de lestriechus. consent for publication not applicable. competing interests there are no competing interests to declare. mgb jb ly nc csm ll mm lw an and sb declare no conflict of interest. advisor consultant review panelboard member speakerhonoraria grantresearch support gb eli lilly janssen organon orimed pharma otsuka pfizer sandoz teva viatris dc abbvie amgen eli lilly freseniuskabi jamp pharma novartis pfizer sandoz tevapharm wm abbvie bms boehringeringelheim care arthritis ltd celgene eli lilly galapagos gilead janssen novartis pfizer ucb. mgb is currently employed by pfizer.",
    "25. j neuroinflammation. 2025 jul 17221186. doi 10.1186s12974025035116. biomarkers of progressive multiple sclerosis decrease following autologous hematopoietic stem cell transplantation. erngren i1 lundblad k2 pavlovic i2 algrety a1 larsson a1 kultima k1 burman j3. author information 1department of medical sciences clinical chemistry uppsala university uppsala sweden. 2department of medical sciences translational neurology uppsala university uppsala sweden. 3department of medical sciences translational neurology uppsala university uppsala sweden. joachim.burmanuu.se. contributed equally background autologous hematopoietic stem cell transplantation ahsct has been increasingly used for treatment of relapsingremitting multiple sclerosis rrms. existing data suggest that ahsct might alter the natural course of multiple sclerosis ms and postpone or even prevent the occurrence of progressive ms. this study aimed to investigate whether three cerebrospinal fluid biomarkers of progressive ms galectin9 gdf15 and ykl40 were affected by treatment intervention with ahsct for rrms. methods rrms patients treated with ahsct at uppsala university hospital between 2011 and 2018 were considered for participation and included if csf samples from baseline and at least one followup were available. csf from healthy volunteers was included as controls. galectin9 and gdf15 concentrations were determined with elisa and ykl40 with electrochemiluminescence. results the final cohort comprised 45 rrms patients and 32 controls. at baseline ms patients had markedly higher csf concentrations of galectin9 and ykl40 and slightly higher gdf15 than controls. following ahsct biomarker concentrations decreased from baseline to the 1year followup with a median iqr of 454 357553 vs. 408 328495 pgml p 0.0002 for galectin9 49 3879 vs. 45 35 to 75 pgml p 0.012 for gdf15 and 100 54164 vs. 58 4392 ngml p 0.0001 for ykl40. galectin9 and ykl40 concentrations decreased further and were even lower at the 2year followup median iqr 408 328495 vs. 376 289478 pgml p 0.0009 for galectin9 and 62 3796 vs. 56 3083 ngml p 0.0001 for ykl40. thereafter the levels of all biomarkers were stable throughout the followup. conclusion treatment with ahsct was associated with sustained reductions in biomarkers linked to progressive ms indicating its potential not only to achieve lasting remission but also to delay or prevent transition to spms. however additional studies are necessary to confirm these findings and elucidate their longterm clinical significance. 2025. the authors. doi 10.1186s12974025035116 pmid 40676588 indexed for medline conflict of interest statement declarations. ethics approval and consent to participate the study was approved by the regional ethical review board in uppsala dnr 2008182 20104501 and 20120801. all participants provided written informed consent. competing interests the authors declare no competing interests.",
    "26. rheumatol int. 2025 jul 17458172. doi 10.1007s00296025059205. anticitrullinated protein antibodies may be prognostic factor for vascularization of the synovial membrane in patients with high activity of ra. jakubaszek m1 kwiatkowska b2 paza m2 maliska m2. author information 1national institute of geriatrics rheumatology and rehabilitation in warsaw warszawa poland. michal.jakubaszekspartanska.pl. 2national institute of geriatrics rheumatology and rehabilitation in warsaw warszawa poland. this singlecenter study aimed to evaluate relationship between the concentration of anticitrullinated protein antibodies acpa and the degree of synovial perfusion in patients with high disease activity of rheumatoid arthritis ra. the study enrolled 60 patients diagnosed with ra and group of 20 patients with psoriasis arthritis psa. different laboratory variables were assessed and particularly acpa uml disease activity was calculated by das 28esr and simplified disease activity score sdai. the degree of the synovial membrane vascularization was assessed using power doppler us pdus and additionally vascularity index was measured by pdus index index in the roi region of interest. correlation between the concentration of acpa and index in ra group was confirmed as week positivity indicating that acpa may be a prognostic factor for vascularization of the synovial membrane in patients with ra. 2025. the authors. doi 10.1007s00296025059205 pmid 40676328 indexed for medline conflict of interest statement declarations. conflict of interest not declared. ethical approval the study received a positive opinion from the bioethics committee at the national institute of geriatrics rheumatology and rehabilitation called bioethics committee at the national institute of geriatrics rheumatology and rehabilitation in warsaw decision no kbt622018 on the day 06.02.2018. each participant signed the informed consent to participate in the study. informed consent each participant signed the informed consent to participate in the study.",
    "27. rheumatol int. 2025 jul 17458173. doi 10.1007s0029602505927y. rheumatoid hand massage therapy to mitigate sarcopenia and improve patients quality of life a hypothesis. kocyigit bf1 zimba o234 yessirkepov m56 khojakulova u7. author information 1department of physical medicine and rehabilitation university of health sciences adana city research and training hospital kla district dr. mithat zsan boulevard 4522. street no28 yreir adana trkiye. bfk2701hotmail.com. 2department of clinical rheumatology and immunology university hospital in krakow krakow poland. 3national institute of geriatrics rheumatology and rehabilitation warsaw poland. 4department of internal medicine n2 danylo halytsky lviv national medical university lviv ukraine. 5department of chemical disciplines biology and biochemistry south kazakhstan medical academy shymkent kazakhstan. 6center for life and health sciences national academy of sciences under the president of the republic of kazakhstan almaty kazakhstan. 7department of emergency medicine and nursing south kazakhstan medical academy shymkent kazakhstan. rheumatoid arthritis ra is a systemic inflammatory disorder frequently associated with sarcopenia a gradual decline in skeletal muscle mass and strength. hand sarcopenia in ra leads to functional deterioration and diminished quality of life. although conventional methods such as exercise and nutrition are typically used current evidence suggests that massage therapy may offer advantages through antiinflammatory circulatory and anabolic pathways. this hypothesisdriven article proposes that targeted hand massage may alleviate sarcopenia in ra by enhancing local perfusion modulating immunological responses mitigating oxidative stress and stimulating muscleregenerative pathways. experimental investigations in animals and humans have demonstrated that massage can activate mechanotransduction signaling enhance muscle protein synthesis stimulate satellite cell activity and reduce inflammatory mediators including tumor necrosis factoralpha and interleukin6. moreover enhancements in handgrip strength and muscle oxygenation have been documented after mechanical interventions. small sample sizes diverse methodologies and the absence of standardized massage procedures limit the clinical validity of the data. randomized controlled trials involving ra patients with compromised hand function and sarcopenia are necessary to explore this hypothesis. standardized outcome measures such as handgrip strength disease activity scores muscle tissue imaging and inflammatory biomarkers are required to assess efficacy. if verified massage therapy may provide a noninvasive lowrisk complement to established care potentially enhancing muscle function and quality of life in ra patients with sarcopenia. 2025. the authors under exclusive licence to springerverlag gmbh germany part of springer nature. doi 10.1007s0029602505927y pmid 40676220 indexed for medline conflict of interest statement declarations. conflict of interest the authors declare no conflicts of interest. ethical approval not required. informed consent since there are no human participants informed consent is not required. declaration of generative ai and aiassisted technologies in the writing process none.",
    "28. nat commun. 2025 jul 171616590. doi 10.1038s41467025619237. nearinfrared lightdriven metabolic reprogramming of synoviocytes for the treatment of rheumatoid arthritis. zhang h1 jia j1 liu h1 han h2 li q34. author information 1key laboratory for molecular enzymology and engineering of ministry of education school of life sciences jilin university changchun 130012 china. 2key laboratory for molecular enzymology and engineering of ministry of education school of life sciences jilin university changchun 130012 china. hanhaobojlu.edu.cn. 3key laboratory for molecular enzymology and engineering of ministry of education school of life sciences jilin university changchun 130012 china. quanshunjlu.edu.cn. 4center for supramolecular chemical biology jilin university changchun 130012 china. quanshunjlu.edu.cn. rheumatoid arthritis is a common autoimmune disease characterized by chronic synovial inflammation and joint destruction primarily driven by an imbalanced cellular metabolism and inflammatory microenvironment. while gene therapy offers a promising therapeutic approach its effectiveness is limited by the challenges of nonspecific gene expression in healthy tissues. here we develop a gene delivery system namely appc in which nearinfrared nirresponsive gold nanorods are coated with chondroitin sulfatemodified polyethyleneimine to facilitate the heatresponsive targeted delivery of heme oxygenase 1 ho1 gene. the appc shows favorable transfection efficiency due to its targeting ability and significantly facilitates ho1 expression under nir irradiation. the combination of appcpho1 and nir can effectively reprogram the cellular metabolism and repolarize the macrophages and fibroblastlike synoviocytes thereby inhibiting inflammation by suppressing glycolysis. meanwhile appc can specifically enhance the ho1 expression in inflamed tissues through nirmediated the activation of heat shock protein 70 promoter ensuring the precise gene expression via photothermal conversion. in a collageninduced arthritis model appcpho1 under nir irradiation exhibits potent therapeutic efficacy restoring the articular microenvironmental homeostasis and mitigating the symptoms of rheumatoid arthritis. these findings highlight the potential of appcpho1 nanoparticles in the gene therapy of rheumatoid arthritis and other inflammatory diseases. 2025. the authors. doi 10.1038s41467025619237 pmid 40676021 indexed for medline conflict of interest statement competing interests the authors declare no competing interests.",
    "29. int rev neurobiol. 202518289119. doi 10.1016bs.irn.2025.04.024. epub 2025 jul 4. autoantibodies in myasthenia gravis. fichtner ml1 horstkorte l1 snchez navarro bg1 schmidt h1 cabraal i2 waters pj2 leite mi3. author information 1department of neurology and experimental neurology charit universittsmedizin berlin berlin germany. 2medical sciences division nuffield department of clinical neurosciences university of oxford oxford united kingdom. 3medical sciences division nuffield department of clinical neurosciences university of oxford oxford united kingdom. electronic address maria.leitendcn.ox.ac.uk. autoimmune myasthenia gravis mg is a disease characterized by fatigable muscle weakness and autoantibodies. it can be divided by the presence of serum autoantibodies into two major categories where immunoglobulin g igg against either the acetylcholine receptor achr or muscle specific kinase musk causes fatigable muscle weakness. the clinical relevance of lowdensity lipoproteinreceptor related protein4 igg lrp4 is debated. these antibodies disrupt neuromuscular transmission via different mechanisms achr antibodies mostly of igg1 and igg3 subclass can activate complement leading to a simplification of the nmj architecture block acetylcholine binding to its receptor to prevent channel opening and internalize achr. by contrast musk antibodies mostly of the igg4 subclass impair musklrp4 interactions and lrp4 antibodies may interfere with agrininduced clustering. once these antibody targets were identified the development of antibody assays began. patrick and lindstrom made the landmark discovery that antibodies against soluble achr caused acute flaccid paralysis in immunized rabbits which kickstarted test development. the first and until recently most useful test was the radioimmunoassay ria where achr radiolabeled with toxin from venomous snakes allowed quantitative measurement of achrigg. most recently the clustered achr cellbased assays cba provide a significant improvement in test sensitivity over all other methods. musk assays followed a similar but shorter path. the accurate detection of achr and musk antibodies has a crucial role in supporting the clinical diagnosis and management of mg which includes a diverse population of patients with a wide range of clinical manifestations disease severity and response to standard and new therapies. in this chapter we highlight how distinct targetspecific igg autoantibodies cause neuromuscular transmission defects and subsequently shape disease manifestations in the different mg antibody subgroups. we review the evolution of diagnostic assays from early ria to modern cba and addresses interpretative pitfalls particularly in borderline or seronegative cases. finally the authors address the significance of accurate autoantibody detection in the diagnosis and management of patients with one of the antibody mg subtypes as well as in patients with other autoimmune conditions and thymic malignancies. copyright 2025. published by elsevier inc. doi 10.1016bs.irn.2025.04.024 pmid 40675742 indexed for medline",
    "30. int rev neurobiol. 20251826788. doi 10.1016bs.irn.2025.04.023. epub 2025 may 12. thymic physiology and pathophysiology in myasthenia gravis. dragin n1 le panse r2. author information 1sorbonne university inserm institute of myology center of research in myology paris france. 2sorbonne university inserm institute of myology center of research in myology paris france. electronic address rozen.lepanseupmc.fr. the thymus is a central lymphoid organ responsible for tcell development and maturation and is crucial in adaptive immunity. this organ creates a specialized environment for thymocyte differentiation and positivenegative selection ensuring the survival of functional and selftolerant t cells while eliminating autoreactive clones. this process which is known as tcell education involves interactions between developing t cells and stromal cells primarily thymic epithelial cells which present tissuespecific antigens. proper thymus function remains vital for maintaining immune homeostasis. however thymic abnormalities have been implicated in myasthenia gravis mg where the thymus often exhibits lymphofollicular hyperplasia or thymomas which may trigger an autoimmune response against the acetylcholine receptor at the neuromuscular junction. this leads to impaired neuromuscular transmission and characteristic muscle weakness. understanding the etiological mechanisms underlying thymic alterations associated with mg is crucial for elucidating immune dysregulation resulting from an abnormal thymus which may persist even posttherapeutic thymectomy. copyright 2025. published by elsevier inc. doi 10.1016bs.irn.2025.04.023 pmid 40675741 indexed for medline",
    "31. int rev neurobiol. 20251824366. doi 10.1016bs.irn.2025.04.035. epub 2025 may 20. contribution of cellular immune dysregulation to myasthenia gravis pathology. bayer ac1 nowak rj2 oconnor kc3. author information 1department of neurology yale school of medicine new haven ct united states department of immunobiology yale school of medicine new haven ct united states. 2department of neurology yale school of medicine new haven ct united states. 3department of neurology yale school of medicine new haven ct united states department of immunobiology yale school of medicine new haven ct united states. electronic address kevin.oconnoryale.edu. myasthenia gravis mg is an autoimmune disorder in which autoantibodies attack proteins at the neuromuscular junction resulting in impaired neuromuscular transmission. like other autoimmune diseases mg arises when the immune system fails to distinguish self from nonself attacking and damaging normal tissues. the pathological response involves not only b cells responsible for autoantibody production but also t cells which provide essential support for b cell pathogenicity. while the precise triggers of this abnormal immune response remain undefined mg is recognized as a multifactorial disease influenced by immune dysregulation along with genetic and environmental factors. this chapter explores the complex immunopathology of mg highlighting how these factors collectively contribute to disease development. we examine the physiological development of t and b cell compartments the tolerance checkpoints designed to prevent autoimmunity and the consequences of their failure. finally we discuss the dysregulation of these cellular compartments in mg emphasizing their roles in disease progression the persistence of autoimmunity and responses to treatment. copyright 2025. published by elsevier inc. doi 10.1016bs.irn.2025.04.035 pmid 40675740 indexed for medline",
    "32. j extracell vesicles. 2025 jul147e70134. doi 10.1002jev2.70134. extracellular vesicles derived from streptococcus anginosus aggravate lupus nephritis by triggering tlr2myd88nfb signalling in nk cells. gong y123 jin l12 duan l12 xiao j12 li y4 wang h12 wang h12 lin w12 zhang y12 gan x12 pang s12 qiu y125 lai w6 zheng l127 li h12. author information 1department of laboratory medicine guangdong provincial key laboratory of precision medical diagnostics guangdong engineering and technology research center for rapid diagnostic biosensors guangdong provincial key laboratory of singlecell and extracellular vesicles nanfang hospital southern medical university guangzhou p.r. china. 2guangdong provincial clinical research center for laboratory medicine nanfang hospital southern medical university guangzhou p.r. china. 3department of internal medicine division of hematology university of maastricht maastricht the netherlands. 4department of laboratory medicine foshan hospital of traditional chinese medicine guangzhou university of chinese medicine foshan p.r. china. 5huayin medical laboratory center co. ltd guangzhou p.r. china. 6department of rheumatology and immunology nanfang hospital southern medical university guangzhou p.r. china. 7state key laboratory of multiorgan injury prevention and treatment nanfang hospital southern medical university guangzhou p.r. china. systemic lupus erythematosus sle has been linked to gut microbiome dysbiosis notably an overabundance of streptococcus anginosus however the impact of this microbial imbalance on disease pathogenesis remains unclear. here we investigated the contribution of s. anginosusderived extracellular vesicles saevs to sle progression with an emphasis on lupus nephritis ln. fiftyfour sle patients and 43 healthy controls hc were recruited. the faecal blood and serum samples from participants were collected. sle disease activity sleda was evaluated by the sleda index sledai. stool s. anginosus abundance was quantified by quantitative pcr nk cell activation by flow cytometry and serum proinflammatory cytokines profile by elisa. lupusprone mrllpr mice were orally administered saevs to evaluate in vivo inflammatory responses renal nk cell activation and renal histopathological changes. s. anginosus levels were significantly elevated in sle patients relative to hc positively correlated with sledai scores and nk cell cytotoxicity. in vitro saevs stimulation of patient nk cells significantly heightened proinflammatory mediator production granzyme b tnf increased cytotoxicity and downregulated inhibitory receptors tim3 nkg2a tigit compared to control evs from s. salivarius ssevs. mechanistically lipoteichoic acid lta within saevs engaged tolllike receptor 2 tlr2 on nk cells activating myd88nfb signalling pathway. in mrllpr mice saevs treatment increased renal immune complex deposition upregulated renal nk cell activation markers nkp44 nkp46 and exacerbated ln pathology with greater immune cell infiltration and inflammatory cytokine levels. furthermore nk cell depletion with antink1.1 antibodies significantly prolonged survival in saevs administered mice. thus saevs exacerbate sle by hyperactivating nk cells via the tlr2myd88nfb pathway leading to amplified systemic inflammation and aggravated ln. these findings underscore the potential of targeting saevs for therapeutic intervention in sle. 2025 the authors. journal of extracellular vesicles published by wiley periodicals llc on behalf of the international society for extracellular vesicles. doi 10.1002jev2.70134 pmid 40673809 indexed for medline",
    "33. front immunol. 2025 jul 2161588486. doi 10.3389fimmu.2025.1588486. ecollection 2025. the path less traveled the noncanonical nfb pathway in systemic lupus erythematosus. montano h1 allen ic1 reilly cm2. author information 1department of biomedical sciences and pathobiology virginiamaryland college of veterinary medicine virginia polytechnic institute and state university blacksburg va united states. 2edward via college of osteopathic medicine blacksburg va united states. systemic lupus erythematosus sle is an autoimmune disease in which autoantibody production and cytokine dysregulation leads to systemic organ and tissue damage that can result in mortality. although various environmental hormonal and genetic factors can contribute to disease pathogenesis the cause of this disease is not known. traditional treatment for this disease is centered around limiting inflammation using a variety of immunosuppresants including glucocorticosteroids as well as other therapeutics including antimalarial drugs. more recently selective immunosuppresives and biologics including belimumab a baff monoclonal antibody and anifrolumab a monoclonal antibody that selectively binds to type 1 interferon receptor infar1 blocking the biological activity of type 1 ifn have been used with various success. it should be noted that baff is of particular relevance as signaling through baffr is a well characterized mechansim for noncanonical nfb signaling. while the canonical nfb pathway has been well studied and reported the role of the noncanonical nfb pathway has been less investigated as to its role in autoimmunity. this pathway has been implicated in influencing proinflammatory immune responses while also regulating lymphocyte development. in this review we aim to provide clarity on the relationship between the noncanonical nfb pathway and the role it plays in pathogenesis of sle. the objective of this review is to summarize recent findings of the relationship of this pathway in autoimmunity and more specifically in lupus pathogenesis. copyright 2025 montano allen and reilly. doi 10.3389fimmu.2025.1588486 pmcid pmc12263575 pmid 40672954 indexed for medline conflict of interest statement the authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.",
    "34. stem cell res ther. 2025 jul 16161380. doi 10.1186s1328702504525w. overexpression of sox4 in mscs inhibits cellular senescence and enhances therapeutic efficacy in systemic lupus erythematosus. qi j12 zhao x2 gao x2 zhu x23 wang j2 liu j2 wei j4 li x5 gao b6. author information 1division of nephrology affiliated zhongshan hospital of dalian university dalian liaoning china. 2department of immunology college of basic medical science dalian medical university dalian liaoning china. 3medical genetics and prenatal diagnosis center the third affiliated hospital of zhengzhou university maternal and child health hospital of henan province zhengzhou china. 4department of immunology college of basic medical science dalian medical university dalian liaoning china. weijingdl126.com. 5department of immunology college of basic medical science dalian medical university dalian liaoning china. lixia0416dmu.edu.cn. 6division of nephrology affiliated zhongshan hospital of dalian university dalian liaoning china. bihugao2020163.com. contributed equally background mesenchymal stem cells mscs are widely used in treating autoimmune diseases. however replicative senescence limits the quantity and quality of mscs during population doublings in vitro. transcription factor sox4 is a crucial regulator of cell fate and stemness. this study aims to explore the role of sox4 in senescence of mscs and enhance their therapeutic efficacy in systemic lupus erythematosus sle. methods in earlypassage mscs p3 latepassage mscs p8 sox4 downregulated p3mscs or sox4 overexpressed p8mscs cell morphology mitochondrial reactive oxygen species mtros senescenceassociated galactosidase sagal activity cell proliferation rate senescenceassociated secretory phenotype sasp factors cell cycle suppressors the immunosuppressive effects on t cell activation and proliferation and the expression levels of sox4 were determined. imiquimod induced sle mice were transplanted with p3mscs and p8mscs or control and sox4 overexpressed p8mscs and clinical symptoms were assessed. results compared to p3mscs p8mscs display a senescent phenotype increased mtros sagal activity sasp factors and cell cycle suppressors p53 p21 and p16. additionally p8mscs have a reduced immunosuppressive function on t cell activation and proliferation and express lower levels of sox4. downregulation of sox4 in p3mscs promotes cellular senescence and impairs their immunosuppressive function. conversely overexpression of sox4 in p8mscs ameliorates cellular senescence and enhances their immunosuppressive function. furthermore transplantation of p3mscs or sox4overexpressing p8mscs demonstrates greater therapeutic significantly efficacy in sle mice compared to p8mscs. conclusions taken together these findings suggest that downregulation of sox4 induces senescence in mscs and impairs their immunosuppressive function. targeting sox4 in mscs may therefore represent a promising therapeutic approach for the treatment of sle. 2025. the authors. doi 10.1186s1328702504525w pmcid pmc12269280 pmid 40671148 indexed for medline conflict of interest statement declarations. ethics approval and consent to participate the study was approved by the ethics committee of the second hospital of dalian medical university 2023 253 approval date 8 october 2023. title of the approved project study on pathogenesis and immunotherapy of patients with autoimmune diseases. the patients or their guardians or legally authorized representatives provided written informed consent for the use of the blood samples or ucmscs. the animal experiment was approved by the animal ethical committee of dalian medical university aee24013 approval date 16 may 2024. title of the approved project study on pathogenesis and treatment of autoimmune diseases. liaoning changsheng biological co. ltd cse2023011005 approval date 30 august 2023. title of the approved project study on pathogenesis and treatment of sjgrens syndrome and systemic lupus erythematosus. consent for publication not applicable. competing interests the authors declare that they have no competing interests.",
    "35. bmj open. 2025 jul 16157e090646. doi 10.1136bmjopen2024090646. telitacicept for systemic lupus erythematosus protocol of a systematic review and metaanalysis. ren x12 zhao p12 zhang j12 yu x12 zhai w32. author information 1department of pediatrics the first affiliated hospital of henan university of chinese medicine zhengzhou henan china. 2college of pediatrics henan university of chinese medicine zhengzhou henan china. 3department of pediatrics the first affiliated hospital of henan university of chinese medicine zhengzhou henan china zhws65415sina.com. introduction systemic lupus erythematosus sle is a chronic and complex multisystem autoimmune disease with high mortality. telitacicept is a new strategy for the treatment of sle inhibiting the maturity proliferation and differentiation of b cells and thus reduces disease activity. however the effectiveness and safety of telitacicept in patients with sle are not yet established. methods and analysis five english databases pubmed embase web of science cochrane central register of controlled trials cumulative index of nursing and allied health literature and four chinese databases china national knowledge infrastructure wanfang data china science and technology journal database and sinomed will be searched from database inception to 1 june 2025. two investigators will independently conduct study selection data extraction and quality assessment. outcomes include disease activity incidence of flares organ damage several immunerelated laboratory parameters and adverse events. risk ratio with 95 ci and mean difference or standardised mean difference will be used as measures of effect sizes in order to pool the data using either a randomeffect model or fixedeffect model according to the heterogeneity of studies. subgroup analysis and sensitivity analysis will be performed to explore the source of heterogeneity and evaluate the robustness of the results. we will use the risk of bias 2 tool and risk of bias in nonrandomized studies of interventions tools to assess the quality of the included studies and use the grade grading of recommendations assessment development and evaluation system to assess the certainty of evidence. ethics and dissemination no ethical approval is required since this review is based on previously published studies. the findings of this study will be presented at international conferences or published in a peerreviewed journal. prospero registration number crd42024558180. authors or their employers 2025. reuse permitted under cc bync. no commercial reuse. see rights and permissions. published by bmj group. doi 10.1136bmjopen2024090646 pmid 40669896 indexed for medline conflict of interest statement competing interests none declared.",
    "36. sci rep. 2025 jul 1515125481. doi 10.1038s4159802506170y. serum untargeted metabolomics alterations in systemic lupus erythematosus patients with elevated serum ferritin. li n1 chai r1 xu x12 xu q3 liang j12 wang d12 zhang h12 feng x12 geng l456 sun l789. author information 1department of rheumatology and immunology nanjing drum tower hospital clinical college of nanjing medical university nanjing china. 2department of rheumatology and immunology the affiliated drum tower hospital of nanjing university medical school nanjing china. 3division of sports medicine and adult reconstructive surgery department of orthopedic surgery the affiliated drum tower hospital of nanjing university medical school nanjing china. 4department of rheumatology and immunology nanjing drum tower hospital clinical college of nanjing medical university nanjing china. genglinyu1987163.com. 5department of rheumatology and immunology the affiliated drum tower hospital of nanjing university medical school nanjing china. genglinyu1987163.com. 6department of rheumatology and immunology nanjing drum tower hospital clinical college of nanjing university of chinese medicine nanjing china. genglinyu1987163.com. 7department of rheumatology and immunology nanjing drum tower hospital clinical college of nanjing medical university nanjing china. lingyunsun2012163.com. 8department of rheumatology and immunology the affiliated drum tower hospital of nanjing university medical school nanjing china. lingyunsun2012163.com. 9department of rheumatology and immunology nanjing drum tower hospital clinical college of nanjing university of chinese medicine nanjing china. lingyunsun2012163.com. contributed equally this study investigated the alterations in serum metabolic profile in systemic lupus erythematosus sle patients with increased levels of serum ferritin. 52 sle patients were divided into two groups based on their ferritin levels. the metabolomic profile was identified using nontargeted metabolomics technology uhplcmsms and analyzed by principal component analysis pca orthogonal partial least squares discrimination analysis oplsda roc analysis and pathway analysis. results showed that sle patients with high ferritin levels had increased hematologic involvement and elevated levels of inflammatory markers including procalcitonin pct alanine transaminase alt and aspartate transaminase ast. additionally there was decreased levels of albumin and cd4 t cell counts. a distinct metabolic profile was found in the highferritin sle group with significant changes in metabolites and metabolic pathways. potential correlations between differential metabolites and clinical features were identified including associations with pct interleukin6 il6 erythrocyte sedimentation rate esr creactive protein crp albumin alt ast immunoglobulin g igg and cd3cd4 t cell. the findings confirm elevated serum ferritin is associated with hematology involvement and offer insights into the pathology and targeted therapeutic strategies of sle. 2025. the authors. doi 10.1038s4159802506170y pmcid pmc12264283 pmid 40664755 indexed for medline conflict of interest statement declarations. competing interests the authors declare no competing interests. ethical approval all participants gave their written informed consent approved by the ethics committee of the drum tower clinical medical school of nanjing medical university in accordance with the declaration of helsinki.",
    "37. lupus sci med. 2025 jul 15122e001608. doi 10.1136lupus2025001608. clinical evaluation of the novel digital liquid chip method for antidsdna detection in sle. bai y1 yu r12 xue c1 wang q1 tian x1 zeng x1 li m1 hu c3. author information 1department of rheumatology and clinical immunology peking union medical college hospital chinese academy of medical sciences peking union medical college national clinical research center for dermatologic and immunologic diseases ncrcdid ministry of science technology key laboratory of rheumatology and clinical immunology ministry of education beijing peoples republic of china. 2eightyear medical doctor program chinese academy of medical sciences peking union medical college beijing peoples republic of china. 3department of rheumatology and clinical immunology peking union medical college hospital chinese academy of medical sciences peking union medical college national clinical research center for dermatologic and immunologic diseases ncrcdid ministry of science technology key laboratory of rheumatology and clinical immunology ministry of education beijing peoples republic of china huchaojun818qq.com. contributed equally objective this study aims to evaluate the diagnostic performance of the digital liquid chip method dlcm compared with indirect immunofluorescence iif and chemiluminescent immunoassay clia for antidoublestranded dna dsdna antibody detection in sle. methods the retrospective study consecutively enrolled 1349 patients including 698 with sle and 651 with other autoimmune diseases at peking union medical college hospital. antidsdna antibodies were detected using iif euroimmun luebeck germany clia yhlo shenzhen china and dlcm livzon zhuhai china. the sensitivity specificity and area under the curve auc of each method and combination were compared at the recommended manufacturer cutoffs. the agreement between methods and the association between antibody levels and clinical characteristics including disease activity complement levels and organ involvement were also evaluated. results all methods exhibited high specificity while iif performed best 98.5 significantly greater than clia 96.3 and dlcm 96.6 p 0.05. clia demonstrated the highest sensitivity 48.1 outperforming iif 36.0 and dlcm 41.4 p0.001. cohens kappa indicated substantial positive agreement between dlcm and clia 0.67 and moderate agreement between iif and the other methods 0.520.55. combining iif with dlcm or clia improved diagnosis performance with iifclia achieving the highest sensitivity 54.0 accuracy 74.1 and auc 0.75. moreover antidsdna positivity was strongly associated with lower complement levels c3 0.71 vs 0.90 gl in dlcm vs dlcm p0.001 and moderatesevere disease activity 65.0 dlcm positive. dlcm uniquely predicted musculoskeletal involvement 55.3 vs 44.7 p0.01. however the diagnostic performance for renal involvement was limited sensitivity 46.9 specificity 56.3 auc0.52. conclusions dlcm demonstrated substantial agreement with clia and held potential for sle diagnosis and monitoring. a multiassay strategy using a sensitive assay like clia or dlcm for initial screening and a highly specific assay like iif for confirmation optimises diagnostic performance for antidsdna antibody detection in sle. authors or their employers 2025. reuse permitted under cc bync. no commercial reuse. see rights and permissions. published by bmj group. doi 10.1136lupus2025001608 pmcid pmc12265827 pmid 40664440 indexed for medline conflict of interest statement competing interests none declared.",
    "38. clin lab. 2025 jul 1717. doi 10.7754clin.lab.2025.241217. neutrophillymphocyte ratio and monocytelymphocyte ratio concerning renal injury in patients with lupus nephritis. wu d wang y han x gao h zhang y lou h. background the aim of this study was to investigate the correlation between the neutrophillymphocyte ratio nlr monocytelymphocyte ratio mlr and plateletlymphocyte ratio plr with renal injury in patients with lupus nephritis ln. methods data was obtained from 26 patients with ln and 72 with systemic lupus erythematosus sle who received treatment between january 2021 and october 2022 at the first hospital of heilongjiang university of traditional chinese medicine. venous blood was collected from the patients. we determined blood urea creatinine cr cystatin c cysc and uric acid ua and calculated the nlr mlr and plr. results the nlr and mlr were significantly greater in the ln group compared to sle group p 0.05. spearmans correlation analysis demonstrated that mlr had a positive correlation with ua p 0.05 while plr exhibited a positive correlation with cr and ua p 0.05. the nlr and mlr pvalues were less than 0.05 and the respective areas under the receiver operating characteristic roc curves for each were 0.761 and 0.720. conclusions nlr and mlr are strongly related to renal injury in patients with ln. these ratios demonstrate a reasonable correlation with the commonly used markers of renal injury and have significant clinical value in evaluating impaired renal function in such patients. doi 10.7754clin.lab.2025.241217 pmid 40663085 indexed for medline",
    "39. eur j med res. 2025 jul 14301618. doi 10.1186s4000102502892x. tumor markers level profile in dermatomyositis systemic sclerosis systemic lupus erythematosus rheumatoid arthritis and ovarian cancer. cai jc1 yang l2 xue ys1 wang sb1 zhang l1 duan kn1 gao zw2 li j3. author information 1department of orthopedics xian peoples hospital xian fourth hospital xian 710004 shaanxi china. 2department of clinical laboratory tangdu hospital air force medical university xian 710038 shaanxi china. 3department of orthopedics xian peoples hospital xian fourth hospital xian 710004 shaanxi china. lijun18991950191126.com. contributed equally background autoimmune diseases aid have been showed to be susceptibility to malignancy. this study aimed to analyzed the profile of serum tumor markers in four common autoimmune disease. methods patients with dermatomyositis dm n 132 systemic sclerosis ssc n 77 systemic lupus erythematosus sle n 191 rheumatoid arthritis ra n 160 and ovarian cancer n 250 were included in this study. twelve tumor markers ca724 afp frt nse ca199 ca125 cyfra211 ca153 hcg and he4 levels and abnormal rate in these patients were retrospective statistics. the tumor markers profiles were compared among the different aid. results compared with ovarian cancer ov patients there were no significant differences for the levels and abnormal rates of cyfra211he4ca50frt in aid patients. the levels and abnormal rates of ca724frtca125nse were higher in ov patients than that in aid patients. 75 aid patients have at least one elevated tumor marker. 69.46 aid patients have 25 elevated tumor markers. all the 12 tumor markers were negative in 16.67 19.74 27.23 and 32.70 of dm ssc sle and ra patients. except ca50 the levels of the other eleven tumor markers were significantly different between dmsscslera. except afphcgscc the abnormal rate of the other tumor markers were significantly different between these aid. conclusions the increased levels of tumor makers were common in four major aid and the profile of tumor makers were significantly different among these aid. 2025. the authors. doi 10.1186s4000102502892x pmcid pmc12261861 pmid 40660406 indexed for medline conflict of interest statement declarations. ethical approval and consent to participate the experimental protocol was established according to the ethical guidelines of the helsinki declaration and was approved by the ethics committee of tangdu hospital air force medical university. this study does not contain patient information does not harm the interests of patients and is exempt from informed consent. the need of informed consent were waived by the ethics committee of tangdu hospital fourth military medical university. informed consent not applicable. competing interests the authors declare no competing interests.",
    "40. lupus sci med. 2025 jul 13122e001624. doi 10.1136lupus2025001624. systemic lupus international collaborating clinicsfrailty index predicts hospitalisations in the almenara lupus cohort. singh a1 gamboacrdenas rv23 pimentelquiroz vr23 reteguisokolova c2 rodriguezbellido z24 pastorasurza ca24 perichcampos ra24 alarcn gs56 ugartegil mf73. author information 1internal medicine baptist hospitals of southeast texas beaumont texas usa. 2rheumatology department hospital guillermo almenara irigoyen essalud lima peru. 3grupo peruano de estudio de enfermedades autoinmunes sistmicas universidad cientifica del sur lima peru. 4school of medicine universidad nacional mayor de san marcos lima peru. 5marnix e. heersink school of medicine the university of alabama at birmingham birmingham alabama usa. 6school of medicine universidad peruana cayetano heredia lima peru. 7rheumatology department hospital guillermo almenara irigoyen essalud lima peru mugartecientifica.edu.pe. objectives to evaluate the systemic lupus international collaborating clinicsfrailty index sliccfi as a predictor of hospitalisations in patients with sle from a latin american cohort. methods patients from a singlecentre prevalent cohort were included. the sliccfi was assessed at baseline. hospitalisations their number as well as their duration in days were reported during the first 3 years from the baseline visit. univariable and multivariable negative binomial regressions were performed to determine the association between the baseline sliccfi per 0.05 increase and hospitalisations during followup number and length adjusted for possible confounders. an alternative analysis was carried out after excluding the damagerelated deficits rendering a modified sliccfi. results of the 295 patients included 273 92.5 were female with a mean sd age at diagnosis of 34.8 13.5 years. at baseline the mean sliccfi was 0.18 0.05 with 86 29.2 patients categorised as being frail. the mean number of hospitalisations per patientyear was 0.4 0.8 and the mean number of days hospitalised during the 3year period per patientyear was 3.1 7.6 days. the sliccfi predicted a higher number and days of hospitalisations incidence rate ratio irr 1.671 95 ci 1.385 to 2.016 and irr 2.018 95 ci 1.715 to 2.375 respectively. the modified sliccfi also predicted hospitalisations in both number and days. conclusion the sliccfi predicted hospitalisations in patients with sle independent of other wellknown risk factors. further studies are needed to develop strategies to improve frailty in these patients. authors or their employers 2025. reuse permitted under cc bync. no commercial reuse. see rights and permissions. published by bmj group. doi 10.1136lupus2025001624 pmcid pmc12258343 pmid 40659389 indexed for medline conflict of interest statement competing interests mfug has grant support from janssen he has been speaker for gsk and astrazeneca and he has been part of advisory boards for gsk tecnofarma astrazeneca and ferrer. all other authors declare to have no conflicts of interest.",
    "41. lupus sci med. 2025 jul 13122e001505. doi 10.1136lupus2025001505. assessing grey matter structural alterations in systemic lupus erythematosus using synthetic mri. deng k1 wu c1 qin y1 cui w2 wen j3 jiang m4 long l4 chen bt5. author information 1department of radiology the first affiliated hospital of guangxi medical university nanning guangxi china. 2ge healthcare china beijing china. 3department of rheumatology and immunology the first affiliated hospital of guangxi medical university nanning guangxi china. 4department of radiology the first affiliated hospital of guangxi medical university nanning guangxi china cjr.longlilingvip.163.com jmlgxmugmail.com. 5city of hope national medical center duarte california usa. objectives to assess brain grey matter alterations in patients with sle and their correlation with neuropsychological testing using synthetic mri symri. methods this prospective study enrolled patients with sle and age gender and educationmatched healthy controls hc. study assessments included brain mri using symri and neuropsychological tests minimental state examination mmse montreal cognitive assessment moca digit span test selfrating anxiety scale and selfrating depression scale sds. symri postprocessing and automated anatomical labeling were used for grey matter mapping. correlation analysis was performed to assess the relationship between brain grey matter structural alterations and neuropsychological testing. results 77 patients with sle 57 nonneuropsychiatric sle nonnpsle 20 npsle and 29 hc participants were enrolled. patients with sle showed reduced grey matter volume compared with hc p0.05. the npsle group exhibited more extensive increases in longitudinal t1 and transverse t2 relaxation times in grey matter than the nonnpsle group p0.001. proton density values were lower in patients with sle p0.001. lower brain parenchymal volume correlated with higher sle disease activity index p0.05. lower mmsemoca scores correlated with increased t1t2 in the left medial cingulate and paracingulate gyri p0.05. higher sds scores correlated with increased t1t2 in the left calcarine fissure and surrounding cortex p0.05. these changes were also linked to disease markers c3 c4 immunoglobulin m erythrocyte sedimentation rate p0.05. conclusions grey matter alterations in patients with sle correlate with cognitive impairment depression and disease activity. authors or their employers 2025. reuse permitted under cc by. published by bmj group. doi 10.1136lupus2025001505 pmid 40659388 indexed for medline conflict of interest statement competing interests none declared.",
    "42. front immunol. 2025 jun 27161589853. doi 10.3389fimmu.2025.1589853. ecollection 2025. lactate and lactylation emerging roles in autoimmune diseases and metabolic reprogramming. liu w12 yang r13 zhan y13 yang x4 zeng h13 chen b13 zeng j13 hu t13 hu j5 xiao q6 shao y7 chen x1. author information 1department of rehabilitation medicine the second affiliated hospital jiangxi medical college nanchang university nanchang china. 2queen mary school jiangxi medical college nanchang university nanchang jiangxi china. 3the second clinical medical college jiangxi medical college nanchang university nanchang china. 4the ophthalmology and optometry college jiangxi medical college nanchang university nanchang china. 5department of pharmacy meijiang town shuidong health center ningdu jiangxi china. 6the first clinical medical college jiangxi medical college nanchang university nanchang china. 7department of rehabilitation medicine ganzhou peoples hospital ganzhou china. autoimmune diseases are a set of conditions in which the immune system incorrectly identifies and attacks the bodys own healthy tissue severely compromising patient health. while current treatments can somewhat control disease progression their longterm effectiveness remains limited necessitating the development of more effective therapeutic approaches. lactate and lactylation are critical links between metabolic reprogramming and epigenetics. as an emerging epigenetic modification lactylation induced by lactate is closely associated with the onset of autoimmune diseases. lactylation can be categorized into histone and nonhistone modifications both of which play pivotal roles in cellular functions and pathophysiological processes through distinct regulatory mechanisms. lactylation impacts immune cell function by regulating metabolic reprogramming and signaling pathways. in autoimmune diseases immune cell metabolic reprogramming controls lactylation levels through metabolic byproducts and lactylation in turn modulates the cellular metabolism by altering the transcription and structure of key enzymes. these interconnected processes collectively drive disease progression. to better understand the role of lactate and lactylation in the pathogenesis of autoimmune diseases this review synthesizes the effects on specific immune cells examining their dual effects on immune system function and their particular impacts on two common autoimmune diseasesrheumatoid arthritis ra and systemic lupus erythematosus sle. by combining the established role of lactate in immune metabolic reprogramming with the emerging understanding of the influence of lactateinduced lactylation on epigenetic regulation this paper explores the relationship between lactylation and the progression of autoimmune diseases. this approach aims to enhance the understanding of the interplay between epigenetics and metabolism in autoimmune disease development providing new perspectives for future therapeutic strategies. studies collectively indicate that treatment can be improved through regulating key enzymes involved in lactylation targeting lactate production pathways integrating innovative approaches with current therapies and adopting personalized treatment strategies. copyright 2025 liu yang zhan yang zeng chen zeng hu hu xiao shao and chen. doi 10.3389fimmu.2025.1589853 pmcid pmc12245685 pmid 40655145 indexed for medline conflict of interest statement the authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.",
    "43. bmc nephrol. 2025 jul 12261381. doi 10.1186s12882025042590. lupus nephritis association with idiopathic cd4 t lymphocytopenia a case report of a young man with recalcitrant warts. wang t1 liu s1 liang x1 xue j1 you l1 zhu x2. author information 1division of nephrology huashan hospital fudan university shanghai 200040 china. 2division of nephrology huashan hospital fudan university shanghai 200040 china. xiaoyezhufudan.edu.cn. introduction systemic lupus erythematosus sle is an autoimmune disease in which the immune system is in a disordered state with excessive production of autoantibodies and abnormal functions of immune cells. this imbalance in the immune system alters the bodys defense capabilities against various pathogens. patients with idiopathic cd4 t lymphocytopenia icl have a reduced number of lymphocytes and the function of the immune system is also impaired. human papillomavirus hpv infects human body and mainly lurks and replicates in skin and mucosal cells. case report a 35yearold chinese male was admitted to the nephrology department with a threeyear history of recalcitrant warts and a sixmonth history of generalized edema and fatigue. physical examination identified verruca vulgaris on the limbs and face. laboratory examinations demonstrated cd4 t lymphocytopenia low levels of c3 complement and positive antinuclear antibodies. renal function tests indicated nephrotic syndrome. renal biopsy findings were consistent with class v lupus nephritis ln. based on the 2019 eularacr criteria the patient was diagnosed with systemic lupus erythematosus sle and treated with prednisone and tacrolimus. however after six months no remission was observed. with the administration of belimumab a significant improvement in his renal symptoms and stabilization of cutaneous lesions were noted at the 12month followup. conclusion this particular case emphasizes the significance of taking into account the potential presence of underlying immunodeficiency in patients with recalcitrant warts and formulating appropriate treatment strategies. such patients necessitate meticulous and continuous followup by both the dermatology and immunology specialties to vigilantly monitor the emergence of other diseases associated with icl. belimumab has manifested outstanding efficacy and safety profiles in sle patients with compromised immune function. 2025. the authors. doi 10.1186s12882025042590 pmcid pmc12255965 pmid 40652180 indexed for medline conflict of interest statement declarations. ethics approval and consent to participate no ethical approval was required for this case report. written informed consent was obtained from the patient prior to her inclusion in the study. consent for publication written informed consent was obtained from the patient for publication of the case report and any accompanying images. competing interests the authors declare no competing interests."
  ]
}